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1. Summary 
The present study aims to supply evidence for a functional role of KCNQ channels in the 
thalamus. KCNQ channels are low-threshold activated K+ channels (Jentsch, 2000) mediating 
a slow, non-inactivating and hyperpolarizing K+ current that has been termed M-current for its 
sensitivity to muscarinic modulation (Adams and Brown, 1982). In the CNS, the activation of 
the M-current plays a crucial role in dampening neuronal excitability and in regulating spike 
frequency adaptation (Cooper et al., 2001). A channel dysfunction in early stages of life has 
been suggested to be the cause of several diseases related to altered excitability, such as 
epilepsy and neuropathic pain. While its role has been well investigated in hippocampal, 
striatal and cortical neurons (Tatulian et al., 2001 Yue and Yaari; 2004; Gunthorpe et al., 
2012), investigation of a functional role of these channels in thalamic neurons was neglected 
for decades, due to the lack of spike frequency adaptation in thalamocortical relay (TC) 
neurons. In the work presented here, it is suggested that the relay and processing of sensory 
information in TC neurons is influenced by KCNQ channels. Using a combined in vitro and 
in vivo approach, it is shownthat in the somato-sensory VB nucleus: 
1. KCNQ2 and KCNQ3 channels are present on the membrane of TC neurons; 
2. KCNQ channels in TC neurons play a crucial role in dampening neuronal excitability, 
hyperpolarizing the cell and, thus, in favouring burst-like activity over tonic activity; 
3. KCNQ channels are modulated by endogenous and exogenous analgesic compounds, 
such as β-endorphin and diclofenac; 
4. Activation of thalamic KCNQ channels attenuates thermal nociception, as evidenced 
by an increase of the latency to pain-related behaviour in freely behaving animals; 
5. The subunit composition of KCNQ channels changes during development.  
For the first time, a systematic study of the functional role of KCNQ channels in TC neurons 
of the somato-sensory VB nucleus is provided. The activation of KCNQ channels seems to 
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mediate an analgesic effect by favouring burst-like activity, rendering these channels a 
potential target in pain treatment. Moreover, the developmental changes of channel subunit 
composition may be important for the organization of the somato-sensory system, suggesting 
a possible pathophysiological mechanism in pain sensation. 
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2. Introduction 
Since decades the assumption that KCNQ channels are not relevant for thalamic cell 
functioning, was generally accepted among researchers. More recently, some evidences of 
their expression and functional role in this brain region have been reported (Cooper et al., 
2001; Saganich et al., 2001; Kasten et al., 2007). The present study is the first systematic 
analysis of the expression of KCNQ channels as well as their corresponding M-current in 
thalamic ventrobasal (VB) neurons. Moreover, we demonstrate that the modulation of KCNQ 
channels in thalamic VB cells is important for the regulation of some aspects of somato-
sensory perception.  
 
2.1. The thalamo-cortical system 
The thalamus is considered the major gateway to the cortex because most of the information 
conveyed to the cortex passes through this brain region. This relation between thalamus and 
cortex is referred in the term of “thalamo-cortical system” (Sherman and Guillery, 2006).  
In rodents, the largest part of the diencephalon is occupied by the thalamus. It consists of 
many nuclei that can be functionally and structurally differentiated based on the type of 
information they are processing (Groenewegen and Witter, 2004). Following these 
categorization five main groups can be identified: sensory/motor relay, nonspecific, 
associative, limbic, and ‘gatekeeper’ nuclei. The relay nuclei receive and convey sensory, 
motor, visceral and associative information from the ascending pathways to other brain areas 
and to different layers of the cortex (Steriade, 1991). Nuclei belonging to the relay category 
are: ventral posterior lateral (VPL; somatic sensation) and medial (VPM; somatic sensation 
and taste), lateral (LGN; vision) and medial geniculate (MGN; auditory), ventral anterior 
(VA; motoric) and ventral lateral (VL; motoric) nucleus. The nonspecific group is formed by 
the midline and intralaminar nuclei that are involved in the perception and relay of 
information coming from visceral and arousal regions of the brainstem and forebrain 
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(emotional pain; Houghton et al., 2001; Ren et al., 2009). The associative group of thalamic 
nuclei is comprised of dorsomedial (DM), pulvinar and lateral posterior nuclei which play a 
role in the integration of different sensory stimuli, their interpretation and formation of a 
response. The limbic group consists of anterior (AD) and lateral dorsal (LD) nuclei, and is 
involved in processes of emotion and memory. The only nucleus of the “gatekeeper” group is 
the reticular thalamic nucleus (RTN or NRT) which regulates the communication between 
thalamus and cortex. Unlike other thalamic nuclei it is composed exclusively of interneurons 
(IN; Houser et al, 1980) and projects only to other thalamic targets but not to the cortex 
(Carman et al, 1964; Steriade et al, 1984). 
Most thalamic nuclei consist mainly exclusively of thalamo-cortical relay (TC) neurons which 
function in two basic modes: transfer mode (tonic) and oscillatory mode (burst). The transfer 
mode occurs during wakefulness and is characterized by a firing rate depending on the 
incoming excitation strength, a modality which is considered fundamental for the relay 
function of TC neurons, namely, the ability to transfer information to the cortex. On the other 
hand, during the oscillatory mode the tonic firing rate decreases and the neurons fire bursts of 
action potentials separated by quiescent periods, a modality which is characteristic during 
drowsiness and slow wave sleep (Steriade et al., 1988; Weyand et al., 2001). The regulation 
of the shift between the two firing modes and maintenance of a certain firing pattern requires 
a change in the membrane potential (Guillery and Sherman, 2002) and it is governed largely 
by the modulation of ion channels (intrinsic properties of TC neurons) and membrane 
receptors via release of several endogenous compounds (Llinàs and Steriade, 2006).  
Briefly, the ion channels involved in the regulation of the two firing patterns are:  
 Na+ channels (inactivating Na+ channels, sensitive to TTX and persistent INa (Jahnsen 
and Llinas, 1984a, b)); 
  K+ channels (leak-channels, Ca2+-activated K+ channels, voltage-dependent K+ 
channels which mediate the transient K+ current (IA; McCormick and Pape, 1990 ) and 
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the hyperpolarization-activated cation current (Ih, Pape, 1996; Luthi and McCormick, 
1998)); 
 various Ca2+ channels, chiefly responsible for the change in the firing pattern is the T-
type Ca2+ channel which is activated at potentials negative to –60 mV and gives rise to 
a Ca2+ conductance (IT) and consequently to a depolarization which may become 
regenerative and activates Ca2+-dependent spikes that cause the high frequency burst 
of Na+ -dependent action potentials which crown the crest of the Ca2+ spike. This 
mechanism arises at hyperpolarized values of the membrane potential and mainly 
regulates the burst activity (Llinas and Steriade, 2006). 
Likewise, the release of transmitters from different afferent inputs to the thalamus can 
regulate the firing patterns via modulation of ionotropic and metabotropic receptors 
(McCormick, 1992): 
 the release of glutamate (Glu) from the synaptic terminals of neurons from different 
layers of the cortex and from sensory afferents, activate TC neurons, causing then to 
favour the tonic mode via activation of ionotropic and metabotropic receptors; 
 the release of acetylcholine (ACh) from the parabrachial region of the brainstem and 
noradrenaline (NA) from the locus coeruleus inhibits the K+ conductance via 
activation of metabotropic receptors in the thalamus such that TC neurons are more 
likely to fire in tonic mode (Steriade, 2006; Sherman and Guillery, 2006); 
 the release of serotonin (5-HT) from the raphe nucleus and histamine from the 
hypothalamus promotes tonic firing via activation of metabotropic receptors.  
 the release of GABA from interneurons within the thalamus activates both ionotropic 
and metabotropic receptors, thus promoting burst firing in TC neurons. 
For many years, the dichotomy of tonic firing/wakefulness and bursting/sleep was considered 
a dogma and the tonic firing was thought to be the only mechanism to relay information to the 
cortex (Weyand et al., 2001). But, evidence shows that the burst firing can occur during 
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wakefulness when a sudden stimulus is conveyed to the thalamus, such as visual stimuli 
(Guido et al., 1992; Weyand et al., 2001) or noxious stimuli conveyed via the spino-thalamic 
tract (Jahnsen et al., 1984). Thus, new questions arise concerning the functional meaning of 
bursts occurring during the relay mode of TC neurons. Many authors claim that such an event 
is required to create a situation in which TC neurons are more prone to receive stimuli, a 
condition which has been defined “readiness status” (Steriade, 1988) or “wake up call” 
(Sherman and Guillery, 2006). However, its role is still not well understood.  
 
2.2. The pain system 
Some thalamic nuclei, such as the VB and intralaminar nuclei, have been shown to be 
involved in pain sensation and discrimination. In order to further clarify their role in this 
aspect of the somato-sensory perception a brief overview on the pain system is necessary. The 
expression “pain system” refers to a broad and various set of pathways responsible for 
perception and discrimination of pain. Sensation of noxious stimuli requires the incoming 
signals to be converted into a form that can be interpreted by networks of the peripheral and 
central nervous system (PNS and CNS, respectively; Riley and Boulis, 2006). Different types 
of stimuli are processed in different ways, depending on the nature and quality of the stimulus 
per se. For example, some sensory-discriminative aspects of pain, like duration, localization 
and intensity are associated with the body surface and, in this case, the perception involves the 
visual, auditory and somato-sensory systems (Auvray et al., 2010). The emotional and 
affective aspects of pain are processed from different brain regions, such as the limbic system 
(Bourbia et al, 2010, Pedersen et al, 2007). Since these systems are often structurally and 
functionally overlapping, it is very difficult to schematically classify pain stimuli and their 
processing. Briefly, the sensory processing involves a bidirectional system which consists of 
ascending and descending components. In the first case, the pain information is transmitted by 
peripheral nociceptors to the spinal neurons that project through the ascending fibres (spino-
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thalamic, spino-mesencephalic, spino-reticular and lemnisci), to the sensory relay nuclei in 
the thalamus. Depending on the vigilance state, pain information partially processed by the 
thalamus might be conveyed further to the cerebral cortex. Additionally, the information 
containing the emotional component is directed to the brainstem and deep brain structures, 
which results in the negative reinforcement mediated by the limbic system, usually induced 
by pain. After discrimination the processed information is carried backwards from central 
regions to the periphery via descending routes (Willis and Westlund, 1997, 2008).  
Pain stimuli, resulting e.g. from tissue damage, lead to nociceptive pain, which is a 
physiological response that helps to protect the organism. It serves as an alarm signal 
indicating injuries and/or danger and leads to the initiation of appropriate reactions. 
Physiologically, nociceptive pain is a normal transient process: its symptoms disappear as 
soon as the painful stimulus is removed or the damage is healed and importantly, perception 
of it can be modulated with analgesic compounds (Butera, 2007). Many different types of 
pain can be characterized by their cause and elicited symptoms: acute pain usually refers to a 
short (mechanical or thermal) stimulus; while visceral pain is typically longer lasting induced 
by the release (or injection) of inflammatory substances inside the body. In some cases acute, 
normally transient pain, might convert into a long-lasting chronic and neuropathic pain 
(Bennet et al., 2012; Attal et al., 2012). Neuropathic pain, as a particular case of chronic pain, 
involves an abnormal processing of sensory input usually occurring after direct injury, viral 
infection, damage to nerve or non-neural tissue. It is characterized by a spontaneous 
hypersensitive pain response that typically persists long after the original nerve cause has 
healed (Campbell and Meyer, 2006). This unusually heightened pain response could be 
observed as hyperalgesia (an increased sensitivity to a noxious pain stimulus) or allodynia (an 
abnormal pain response to non-noxious stimulus, e.g. cold, warmth, touch). This kind of pain 
is chronic and debilitating because pain episodes are often resistant to currently available 
pharmacotherapies (Butera, 2007). 
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2.3. VB complex and pain perception 
The ventrobasal complex (VB) in rodents, occupies a 
large part of the ventrolateral thalamic area 
(Groenewegen and Witter, 2004; Fig. 1). It extends 
rostromedial to the MGN and is bordered by the medial 
lemniscus and NRT. It is the main relay station for 
sensory information from the periphery to the cortex 
and consists of two nuclei: the ventral posterolateral 
nucleus (VPL) and the ventral posteromedial nucleus 
(VPM). Both nuclei consist mostly of projecting 
neurons and only very few GABA-ergic neurons (Price, 
1995). The main sensory inputs are directly coming 
from somato-sensory afferents of the spino-thalamic 
tract, originating in the dorsal column nuclei and the 
trigeminal complex of the spinal cord (Lenz, 1992). In 
addition, the VPM and VPL receive afferents from different layers of the somato-sensory 
cortex, many subcortical areas including other thalamic nuclei (such as the NRT) and 
brainstem serotonergic, cholinergic and adrenergic nuclei (Steriade et al., 1988). These 
afferents are conveying nociceptive, tactile and kinaesthetic information from the head and 
the rest of the body (Groenewegen and Witter, 2004). 
The first evidence that pointed to an involvement of the VB complex in nociception was 
reported in the late 1980s. It was shown that, in addition to previously described mechano-
receptive cells, the VPL contains many nociceptive and thermo-receptive neurons (Peschanski 
et al, 1980b; Hellon and Misra, 1973). Moreover, it was shown that the response of 
nociceptive VPL neurons to a noxious stimulus is enhanced during the formalin test, an acute 
inflammation test, (Guilbaud et al, 1986, 1987a, 1987b, 1990) and that the response is more 
Fig. 1. The ventro-basal complex, 
consisting of the ventro-medial and 
ventro-lateral nuclei marked in the red 
inset in a coronal slice from mouse 
brain, modified from Paxinos Atlas 
(1997). 
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prominent during the latest phase of the test, when the inflammation reaches its peak (Huang 
et al., 2006). Additionally, the intra-thalamic injection of the local anaesthetic lidocaine 
induces a profound impairment in the ability to discriminate thermal noxious stimuli in 
monkeys (Bushnell et al., 1991). Electrophysiological recordings performed in anesthetised 
animals suggest also a somatotopic organization of VB because the response of neurons, 
localized in different parts of VPL, can be evoked by mechanic and thermal stimulation of 
different body parts (Koyama et al. 1998; Houghton et al., 2001; Wang et al., 2009). In 
addition, recently, neuronal thalamic response to noxious and innocuous stimuli was assessed 
in mice using the f-MRI technique (Bosshard et al., 2010). 
The crucial role of the VB complex in pain and somato-sensory discrimination has since been 
further established. Nevertheless, many aspects of pain sensation, such as the onset of 
different aversive behaviours at different time points following the stimulus presentation, are 
still not well understood (Price et al, 1995). For example, the pain response to the formalin 
test consists of two different phases: an early and late phase; characterized by different pain-
related behaviours elicited by different mechanisms which both involve VB activation. 
Interestingly, both phase-related pain perceptions can be relieved by intrathalamic injections 
of opioids and other antinociceptive substances (Potes et al, 2006; Pozza et al, 2010; Porro et 
al, 2003). 
Several reports revealed changes of the electrical behaviour of thalamic neurons, especially in 
the VB complex, after injuries to the peripheral nerves (Guilbaud et al, 1990; Rinaldi et al 
1991; Rasmusson et al., 1996), ascending pain pathways (Hirayama et al., 1989; 
Radhakrishnan et al., 1999; Miki et al., 2000; Gerke et al., 2003; Gwak et al., 2010) and 
during chronic inflammation, such as monoarthritis (Neto et al., 2008). These findings suggest 
that the thalamus is involved in the onset and maintenance of neuropathic pain and allodynia, 
a condition that can be reverted or ameliorated by pharmacological modulation of the 
thalamic somatosensory nuclei (Saadè et al., 2006; Ueda et al., 2010). 
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2.4. KCNQ channels 
KCNQ channels (Kv7 channels according to the new nomenclature) are low-threshold 
voltage-activated K+ channels mediating a hyperpolarizing K+ current. KCNQ genes encode 5 
members of the KCNQ channel family: KCNQ1-5 (Brown and Passmore, 2009). Of these, 
four channels (KCNQ2-KCNQ5) are expressed in different cell types of the nervous system, 
while the expression of KCNQ1 is restricted to the heart, peripheral epithelial and smooth 
muscle cells (Jentsch, 2000; Robbins, 2001). 
Each KCNQ subtype exhibits a high homology degree with other proteins belonging to the 
broad K+ channels family. KCNQ channels are tetramers consisting of four subunits (Fig. 2). 
Every subunit is built by six trans-membrane domains (S1-6) and a single pore P-loop that 
forms the selectivity filter. An intracellular part of the S4 domain plays a role as a voltage 
sensor. The amino- and carboxy-termini of the protein are located on the intracellular side of 
the membrane and are rich in phosphorylation sites for the intra-cellular modulation of the 
channel function (Schwake et al., 2006; Howard et al., 2007; Hernandez et al., 2008). 
In vitro experiments demonstrated that all five known KCNQ proteins can form homomeric 
channels, but only a certain combination leads to formation of heteromeric channels, such as 
KCNQ3 and 5, KCNQ3 and 4 as well as KCNQ2 and 3 (Schroeder et al., 1998, 2000; Jentsch, 
2000; Lerche et al., 2000).  
The heteromeric channel resulting from the association of KCNQ2 and KCNQ3 is the most 
abundant in the nervous system and it seems to be the molecular substrate of the M-current 
(Wang et al., 1998). This current was first identified and described more than 30 years ago by 
Brown and Adams (1980) in sympathetic neurons of the frog. Because it is modulated by 
muscarinic agonists it was called M-current and the channels underlying it, were thus termed 
M-channels (Brown and Adams, 1980; Marrion et al., 1989). 
M-current shows a characteristic time and voltage dependency that result in a 
hyperpolarization of the membrane potential when the cell is exposed to an excitatory 
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stimulus (Delmas and Brown, 2005). Therefore, KCNQ channels are not fully open at RMP 
and they play a crucial role in regulating the excitability (e.g. spike frequency adaptation) of 
various peripheral and central neurons, such as hippocampal pyramidal cells and striatal 
neurons (Yue et al., 2004; Peters et al., 2005; Gu et al., 2005; Gunthorpe et al., 2012). KCNQ 
channels are expressed at different cellular locations, such as somato-dendritic and axonal and 
terminal sites. This broad distribution enables them to participate in both pre- and post-
synaptic modulation of basal and stimulated neurotransmission, both inhibitory and excitatory 
(Vervake et al., 2006; Peretz et al., 2007; Hansen et al., 2008).  
 
 
 
2.4.1. KCNQ channel expression in the CNS 
The KCNQ subunits 2 and 3 are expressed in the CNS and are localized at key sites for 
neuronal network oscillations (Cooper et al., 2001). Strong KCNQ2 immunoreactivity has 
been detected in the thalamus (NRT, VPL, VPM), a subpopulation of cholinergic neurons of 
the medial habenula, cerebral cortex, hypothalamus, midbrain, all neuronal populations of the 
Fig. 2. a KCNQ channel subunits have a conventional shaker-like K+ channel structure, with 6 transmembrane 
domains (S1–S6), a single pore (P)-loop that forms the selectivity filter of the pore, a positively-charged fourth 
transmembrane domain (S4) that acts as a voltage sensor and a long intracellular carboxy-terminal tail. Four such 
subunits make up a functional KCNQ channel. The carboxy terminus contains a conserved domain (A domain) 
that determines the subunit specificity of the KCNQ channel assembly. b The carboxy-terminal tail of KCNQ2 
subunits has binding sites for several potential regulatory molecules, as depicted. CaMI and CaMII represent the 
two binding sites for calmodulin (CaM). Modified from Delmas and Brown (2005). 
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hippocampus, basal ganglia, substantia nigra, striatum and ventral-tegmental area (Cooper et 
al., 2001). 
KCNQ3 is mostly expressed in the same regions as KCNQ2. An in situ hybridization study 
showed that centrally localized KCNQ3 channels are highly expressed in the forebrain: cortex 
(all layers), hippocampus (CA2 and CA3), septum, basal ganglia and thalamus (VB complex, 
MGN and LGN; Saganich et al., 2001). 
KCNQ4 is expressed in all cell types of the auditory system, especially in the cochlea (Liang 
et al., 2006). There is also evidence for KCNQ4 expression in murine arteries in co-
localization with KCNQ5 (Ng et al., 2011). KCNQ5 is broadly expressed in the cortex, 
amygdala, caudate-putamen, hippocampus and in the skeletal muscles (Lerche et al., 2000). 
 
2.4.2. Developmental profile of KCNQ channels 
The expression of the four KCNQ channels in the brain differs among various regions. 
Moreover, the stoichiometry of heteromeric channels varies also. For example, KCNQ3 can 
form heteromeric channels by co-assembling with KCNQ2, 4 and 5 (Jentsch, 2000). When it 
is co-assembled with KCNQ2 but also KCNQ5, it mediates M-current with an amplitude 
current that is much bigger than the current mediated by a homomeric KCNQ3 channel 
(Brown and Adams, 1980; Marrion, 1997; Schroeder et al., 2000). Various explanations for 
this phenomenon can be found in the literature. Some authors claim that the difference in 
current amplitudes is due to the existence of several splice variants of KCNQ2 (Pan et al., 
2001; Smith et al., 2001; Hadley et al, 2003). Other authors find the cause for this difference 
in the stoichiometry of the heteromeric KCNQ2/KCNQ3 channels (Cooper et al., 2001; 
Hadley et al., 2003), although the impact of the exact stoichiometry or subunit combination on 
the channel function are not fully understood. 
Regarding the phenomenon of varying current amplitudes dependent on the subunit 
composition, the developmental profile of KCNQ channel expression should be taken into 
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consideration. In fact, many recent studies show differences in the protein expression of 
KCNQ2 and KCNQ3 during ontogenesis. Hadley and colleagues (2003) have shown a 
developmental delay in the expression of KCNQ3 in native ganglionic neurons from rats. 
They found an increased expression starting at post-natal day (P) 7. This remained elevated 
until P45, whereas there was no change in the expression of KCNQ2 and KCNQ5. Previous 
studies pointed out that in the mouse brain, the KCNQ2 levels are high already at P7, whereas 
KCNQ3 levels are very low at P3 and do not increase considerably before P30 (Tinel et al., 
1998). Interestingly, the sensitivity to linopirdine (a KCNQ blocker) increases with the age of 
the animals, reflecting developmental changes in KCNQ channel expression (Safiulina et al., 
2008). In line with above findings are results obtained in humans: the expression of KCNQ2 
in hippocampus is high during foetal life and decreases after birth, whereas expression of 
KCNQ3 increases in late foetal life and stays high during infancy. From a pathophysiological 
point of view, an imbalance in the expression patterns of KCNQ channels could be the cause 
of neonatal epilepsy syndromes (Pena et al., 2006; Kanaumi et al., 2008). 
 
2.4.3. Muscarinic signal transduction 
In the early 80s Brown and colleagues proved that activation of the G-protein cascade, via 
activation of muscarinic receptors M1 and M3, is able to reduce M-current (Brown et al., 
1980). All subsequent experiments trying to understand the signal transduction mechanism 
that modulates M-channel activity were based on this finding. In particular, in vitro 
experiments conducted in Gqα deficient mice, identified subclasses of G-protein: Gq and G11, 
as candidates triggering the signal transduction pathway that modulate M-channel activity 
(Pfallinger et al., 1988; Haley et al., 1998, 2000). 
The subunit Gqα first triggers the activation of phospholipase-C (PLC; Fig. 3), an enzyme that 
is responsible for the hydrolysis of phosphatidylinositol-4,5-biphosphate (PtdIns(4,5)P2 or 
PIP2) and formation of two compounds: inositol-1,4,5-triphosphate (Ins(1,4,5)P3) and 
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diacylglycerol (DAG). Both are second messengers and can trigger activation or deactivation 
of many intra-cellular mechanisms, mainly phosphorylations and changes in the intra-cellular 
Ca2+ concentrations (by inducing Ca2+ release from the internal stores; Marrion et al., 1997; 
Suh et al., 2002, 2004; Ford et al., 2003; Zhang et al., 2003, 2010). It is believed that 
depletion of PIP2 and increase of intra-cellular Ca2+ are the main mechanisms responsible for 
the closing of M-channels. Summarizing, any signal that triggers synthesis of PIP2, decreases 
the intracellular Ca2+ concentration (like cellular hyposmotic conditions; Caspi et al., 2009) or 
de-phosphorylates channel proteins could lead to an enhancement of KCNQ channel 
activation (Li et al., 2005; Hernandez et al., 2008). 
 
 
 
 
 
Fig. 3. KCNQ2–5 channels bind phosphatidylinositol-4,5-bisphosphate (PIP2). PIP2 is required for KCNQ 
channel opening. M1 muscarinic and bradykinin (BK) receptors (B2R) couple to Gq/11 G-proteins and 
activate phospholipase-C (PLC). This leads to hydrolysis of PIP2 to produce inositol-1,4,5-trisphosphate 
(Ins(1,4,5)P3) (IP3) and diacylglycerol (DAG). The local increase in IP3 produces a vigorous release of 
Ca2+ that is sufficient to bind to KCNQ-attached calmodulin and close the channels. Modified from Delmas 
and Brown, 2005. 
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2.4.4. Modulation of M-current  
The activation of several receptors due to agonist binding can lead to a modulation of M-
channels. For example, ACh released from the cholinergic fibres binds to the muscarinic 
receptors M1/M3 (MAChR) and inhibits KCNQ channels, which in turn induces a slow 
depolarization of the postsynaptic neuron (Gahwiler et al., 1985; Cruzblanca, 2006). 
Moreover, the release of serotonin in the human cortex (McCormick and Williamson, 1989), 
activation of endocannabinoid CB1 receptors (Schweitzer, 2000) and release of glutamate and 
purinergic agonists in the superior cervical ganglia (SCG) via activation of mGluR1 and P2Y, 
respectively, can suppress M-current (Charpak et al., 1990; Delmas and Brown, 2005; 
Hernandez et al., 2008; Schicker et al., 2010). Besides neurotransmitters, several other 
endogenous messengers can negatively modulate KCNQ channels: bradykinin (via activation 
of B2 receptors; Delmas and Brown, 2005; Zaika et al., 2007), angiotensin II (via activation 
of AT1 receptors; Zaika et al., 2006), the nerve growth factor (NGF, Jia et al., 2008) and the 
luteinizing hormone (LHRH; Bley et al., 1990). 
Unfortunately, much less is known about the endogenous activation of KCNQ channels. 
There is controversial evidence regarding substance P (SP) which was shown to either 
augment the M-current in DRG neurons (Linley et al., 2012; Lin et al., 2012), or inhibit 
KCNQ channels in sympathetic bullfrog neurons (Adams et al., 1983; Bley et al., 1990). In 
the hippocampal CA1 region, somatostatin, corticostatin and dynorphine A have been 
reported to activate M-current, thereby hyperpolarizing the Vm and reducing neuronal 
excitability (Moore et al., 1988, 1994; de Lecea et al., 1996; Madamba et al., 1999a, b). In 
CA1, an enhanced M-current is due to the activation of somatostatin subtype 4 receptors 
(SSR4; Qiu et al., 2008) and a subsequent activation of arachidonic acid metabolites pathway 
(Schweitzer et al., 1990). Moreover, in neurons of the solitary tract somatostatin produces 
hyperpolarization and depresses excitability via an increased M-current (Jaquin et al., 1988). 
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The pharmacological modulation of KCNQ channels using different exogenous compounds is 
a specific and selective approach for channel characterization studies. Over the last years, a 
variety of K+ blockers and enhancers that strongly and specifically modulate M-current 
through direct binding to KCNQ channels have been identified (Wulff et al., 2009). One of 
those specific channel blockers is linopirdine. It induces closure of KCNQ channels (Aiken et 
al., 1995), and shows low affinity for other K+ channels (Lamas et al., 1997). A similar 
mechanism of action is typical for other specific blockers, XE991 which shows an even 
higher affinity and selectivity for native M-currents than linopirdine (Wang et al., 1998, 2000; 
Robbins et al., 2001; Schroeder et al., 2001; Peretz et al., 2007). The application of KCNQ 
blockers was useful for the identification of M-currents in neurons of the dorsal root ganglion 
and the spinal cord, in which XE991 induces depolarization and an increase of the spike 
frequency (Otto et al., 2006; Rivera-Arconada et al., 2005). 
Among the channel openers are flupirtine, retigabine (Linley et al., 2012; Dalby-Brown et al., 
2006), BMS-204352 (maxipost; Schroder et al., 2001; Korsgaard et al., 2005), diclofenac, 
meclofenamic acid, NH6 (Peretz et al., 2005, 2007), ICA-27243 (Wickenden et al, 2008), 
several acrylamides (Bentzen et al., 2006; Blom et al., 2009) and zinc-pyrithione (Xiong et 
al., 2008). The most frequently used KCNQ channel opener and enhancer is retigabine which 
was shown to activate M-current mediated by heteromeric KCNQ2/KCNQ3 channels among 
the others (Main et al., 2000; Rundfeldt and Netzer, 2000b; Wickenden et al., 2000). 
Retigabine modifies the voltage-dependence of these channels, increases the activation rate, 
favours the open configuration of the channels and slows down the deactivation phase 
(Tatulian and Brown, 2003). It was also found to induce spike frequency adaptation in 
hippocampal (Yue and Yaari, 2005) and spinal cord neurons (Rivera-Arconada and Lopez-
Garcia, 2005). However, at concentrations higher than the one required to modulate KCNQ 
channels, retigabine can interact with the GABA-ergic system indirectly by reducing GABA 
release (Kapetanovic et al., 1995; Rundfeldt and Netzer, 2000a; van Rijin and Willems-van 
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Bree, 2003) and directly by allosteric modulation of the major GABAA receptor isoforms in 
the brain (Wafford, 2005; Gunthorpe et al., 2012). Further investigations showed that 
retigabine does not interact with the ionotropic glutamatergic receptors and that it only weakly 
inhibits Na+ and Ca2+ channels (Gunthorpe et al., 2012). 
 
2.5. KCNQ channels in health and disease 
The peculiarity of the hypothesized mechanism of action of KCNQ channels and their role in 
dampening the cell excitability emphasize their importance in regulation of many 
physiological processes. Dysfunction of KCNQ channels causes severe functional 
consequence that leads to the development of pathophysiological states, and several examples 
of KCNQ-associated diseases are described in literature (Jentsch, 2000; Brown, 2008). A 
mutation of the cardiac KCNQ1 protein most probably induces an alteration in Ca2+ signalling 
and has been linked to the onset of the Hereditary Long-QT Syndrome (LQTS; Park et al., 
2005). Mutations in genes encoding for KCNQ4 and KCNQ5 lead to many other severe 
diseases like cardiac arrhythmia (Wang et al., 1996), impaired transepithelial transport 
(Neyroud et al., 1997), and progressive hearing loss (Kubisch et al., 1999). Mutations in 
KCNQ2 and KCNQ3 heteromeric channels are responsible of benign familial neonatal 
convulsions (BFNC) and other forms of epilepsy (Bievert et al., 1998; Singh et al., 1998; 
Charlier et al., 1998; Jentsch, 2000). Moreover, mutations in either KCNQ2 (Watanabe et al., 
2000) or KCNQ3 as homomeric channels can also induce several epileptic syndromes of 
particular severity (Jentsch, 2000). Compared to other KCNQ channels, KCNQ2/3 
heteromeric channels produce larger currents (Brown and Adams, 1980; Wang et al., 1998; 
Schroder et al., 1998), with slightly different kinetics and sensitivity to openers and inhibitors 
(Hadley et al., 2000) they are very promising targets for novel anticonvulsive drugs. It was 
already shown that retigabine attenuates epileptoform activity in ex vivo and in vivo models of 
epilepsy (Armand et al. 1999; 2000; Dost and Rundfeldt, 2000; Wuttke and Lerche, 2006). 
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Additionally, it attenuates the symptoms in pharmacoresistant cases of epilepsy in human 
preparations, and it successfully completed phase I and II clinical trials as an anticonvulsive 
drug, currently being in phase III trial (Porter et al., 2007a, b). 
 
2.6. KCNQ channels and pain 
Pain perception in the nervous system can be regulated by many endogenous compounds, 
among which are substance P and bradykinin. In fact, intra-peritoneal injection of substance P 
and bradykinin induces acute visceral and inflammatory pain in mice (Potter et al., 1962; 
Mayer et al., 1999; Laird et al., 2000; Kamp et al., 2001). Both substances are also negative 
modulators of KCNQ channels, suggesting involvement of these channels in pain processing. 
On the other hand, KCNQ channels are positively modulated by dynorphine, an opioid 
involved in analgesia and anti-nociception (Tung et al., 1982; Tiseo et al., 1988; Kapitzke et 
al., 2005). Further evidence shows that KCNQ channels expressed in peripheral nerve endings 
are involved in the machinery of receiving and transducing pain signals (Belmonte and Viana, 
2008). In peripheral myelinated axons they have been functionally characterized (Devaux et 
al., 2004) and were found to co-localize with Na+ channels in nodes of Ranvier (Devaux et al., 
2004; Pan et al., 2006). In isolated segments of human sural nerves, retigabine reduced the 
excitability of unmyelinated C-type fibres which mediate pain sensation (Lang et al., 2008). 
Moreover, KCNQ channels are broadly expressed on the cell bodies of primary afferents in 
dorsal root ganglia (DRG), where they are involved in inducing hyperexcitability during 
inflammation (Passmore, 2003; Linley et al., 2008). Also, in a large proportion of dorsal horn 
neurons M-like currents can be recorded after application of retigabine (Rivera-Arconada et 
al., 2004, 2009; Passmore et al., 2012). 
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2.6.1. KCNQ channels and acute pain 
The role of KCNQ channels in modulating acute pain is a controversial issue. Upon activation 
of KCNQ channels via i.p injection of retigabine in rats, Dost and colleagues (2004) showed a 
small increase in latency in the tail-flick test, while in the same test Blackburn-Munro and 
colleagues (2003) observed no changes in the perception of acute pain after injection either of 
retigabine or XE991. Moreover, retigabine and flupirtine attenuate nociception during the 
second phase of the formalin test, a model of acute pain inflammation (Blackburn-Munro et 
al., 2003; Hirano et al., 2007; Capuano et al., 2011). 
 
2.6.2. KCNQ channels and neuropathic pain 
The localization (among other K+ channels) and mechanism of action of KCNQ channels also 
suggest their involvement in appearance and maintenance of the neuropathic pain syndrome. 
This holds true for both, peripheral and central components of the nociceptive system (Rivera-
Arconada et al., 2009) and many findings support this theory. Utilization of neuropathic pain 
models in rodents is a reliable method to reproduce human neuropathic conditions and to 
evaluate the role played by KCNQ channels. Data derived from these studies showed that at 
the peripheral level there is a change in expression of Na+ and K+ channels, with consequent 
appearance of ectopic activity associated with neuropathic symptoms (Rasband et al., 2001; 
Bostock et al., 2005; Hains et al., 2005; Devor, 2006; Roza et al., 2008). Likewise, in 
trigeminal inflammatory neuropathic model (TRG), a transient outward K+ current (IA) was 
shown to be strongly suppressed when compared with IA of naïve animals (Takeda et al., 
2011). Moreover, the partial nerve ligation (PSLN) in rats induces a neuropathic pain 
syndrome which is characterized by a down-regulation of the KCNQ2 gene in the latest stage. 
This suggests a role of KCNQ2 channels in the maintenance of the neuropathic state (Rose et 
al., 2011). 
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In the past, the therapy for neuropathic pain included the use of anticonvulsive drugs 
(gabapentin and pregabalin; Sindrup and Jensen, 1999), however, it was accompanied by 
many side effects. Recently Blackburn-Munro and colleagues (2005) showed that the negative 
side effects are due to the higher concentrations needed for the analgesic effect while the 
dosage required to attenuate anxious behaviour causes less side effect. In the same study, they 
showed that retigabine, like many other KCNQ channel openers, has a positive effect on the 
treatment of neuropathic pain at relatively low concentrations. In other neuropathic models 
with chronic constriction and nerve injury, the injection of retigabine and flupirtine attenuates 
allodynia in the pin prick stimulation to the injured paw (Blackburn-Munro and Jensen, 2003). 
Moreover, in rats with nerve ligation the same compounds induce an analgesic effect to 
thermal and tactile stimulation. Such effects can be reverted by application of the specific 
blocker linopirdine (Dost et al., 2003). The efficacy of analgesic effect induced by KCNQ 
openers is comparable to the effect induced by derivates of opioids such as tramadol, in 
models of mechanic neuropathic pain (Dost et al., 2003), morphine in a model of 
inflammation-induced neuropathic pain (Xu et al., 2010), and ketamine in an acid-induced 
model of allodynia (Nielsen et al., 2004). The evidence of KCNQ channel modulation in the 
periphery and at the central level of the nervous system highlights that these channels are 
good candidates for specific pain treatments (Bi et al., 2011) 
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3. Aim of the study 
Epilepsy, cardiac syndromes and neuropathic pain are serious and severe diseases caused by 
cell excitability dysfunctions and not well understood (Bi et al., 2011). The involvement of 
KCNQ channels in regulating cell excitability and therefore, the appearance and/or 
maintenance of such diseases is relatively new concept introduced only over the last decade. 
These channels are widely expressed in the CNS and evidence of their presence in the 
thalamus was presented in the literature (Cooper et al., 2001; Saganich et al., 2001). Based on 
the non-adapting firing properties of thalamic neurons, a potential functional role played by 
KCNQ channels in the thalamus was neglected for decades. Recently, evidence of functional 
expression has been shown in TC neurons where the inhibition of KCNQ channels enhances 
the firing rate thereby modulating the TC neurons excitability (Kasten et al., 2007). This 
finding opened a new scenario for the study of the role of KCNQ channels in the thalamus. In 
fact, we suggest that the modulation of the KCNQ channels expressed in the thalamus can 
alter the regulation of excitability of TC neurons and subsequent regulation of the relay 
function, i.e. the processing of the sensory information eventually conveyed to the cortex. 
Therefore, this study aims to: 
 understand the functional role of KCNQ channels in the thalamic ventro-basal nuclei 
(VB complex); 
 identify possible endogenous compounds which can modulate KCNQ channels in the 
thalamus; 
 assess the subunit compositions by analysing the current amplitude before and after 
pharmacological modulation in TC neurons, in heterologous expression systems and in 
genetically modified mice (KCNQ3+/-)  
 determine the role of the VB complex and KCNQ channels in the acute pain sensation. 
By combining different in vitro and in vivo techniques, we show a consistent expression of 
KCNQ channels in VB were these channels are functionally involved in regulating the cell 
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excitability. This, in TC neurons, influences the two different firing patterns characteristic of 
these neurons. The evidence herein presented, clearly shows the activation of the slow 
hyperpolarizing M-current and the strong effect on the firing rate: reduction of action 
potential number and frequency after retigabine application and a respective increase after 
XE991 application. The application of synthetic compounds, with different specificity for the 
different KCNQ subunits, helped to understand the nature of the M-current in the thalamus 
and its functional role in the somato-sensory system information processing. 
In freely behaving animals, a correlation between KCNQ activity and pain sensation has been 
found: the intra-thalamic injection of retigabine increased the latency to pain behaviour. This 
effect was region-specific since injection in neighbouring nuclei failed to produce an 
analgesic effect.  
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4. Material and Methods 
4.4. Ex vivo experiments 
4.4.1. Tissue preparation  
All animal work has been approved by local authorities (review board institution: Landesamt 
für Natur, Umwelt und Verbraucherschutz Nordrhein-Westfalen; approval ID numbers: 8.87-
51.05.2010.117). 
C57Bl/6 mice were purchased from Charles River Laboratories (Sulzfeld, Germany) and bred 
in the animal facility of the Institute of Physiology I and their offspring served as subjects at 
post-natal day 15-30. Animals were group-housed in standard dark-light conditions (12 h in 
dark/light cycle) with food and water ad libitum. The animals used for the 
electrophysiological recordings were anesthetised with isoflurane and decapitated; a block of 
brain tissue was rapidly removed from the skull and placed in chilled (2-4 °C) oxygenated 
slicing solution containing (in mM): sucrose, 200; glucose, 10; PIPES, 20; KCl, 2.5; MgSO4, 
10; CaCl2, 0.5; pH 7.35 (adjusted with NaOH). Thalamic slices were prepared as coronal 
sections of 300 µm thickness on a vibratome (Leica VT 1200, Leica, Wetzlar, Germany). 
Prior to recording, slices were kept in an incubation chamber in standard artificial 
cerebrospinal fluid (ACSF) which contained (in mM): NaCl, 125; KCl, 2,5; NaH2PO4 1.25; 
NaHCO3, 24; MgSO4, 2; CaCl2, 2; glucose, 10; pH 7.35 (adjusted with carbogen; a mixture of 
95% O2 and 5% CO2).  
 
4.4.2. Patch-clamp recordings in acute brain slices 
Whole-cell recordings were performed on visually identified TC neurons of the ventro-basal 
complex (VB) at room temperature. Slices were transferred to a recording chamber where 
they were kept in a solution containing (in mM): NaCl, 120; KCl, 2.5; NaH2PO3 1.25; 
NaHCO3, 22; C6H12O6, 20; CaCl2, 2; MgSo4, 2; pH 7.35 (adjusted with carbogen). 
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Electrical activity was measured with electrodes made out of borosilicate glass capillaries 
(GC150TF-10, Clark Electromedical Instruments, Pangbourne, UK) pulled on a vertical 
puller and connected to an EPC-9 amplifier (HEKA Elektronik, Lamprecht, Germany). 
Pipettes were filled with one of two solutions which contained (in mM):  
1) standard solution: NaCl, 10; K-Gluconate, 88; K3-citrate, 20; HEPES, 10; BAPTA, 3; 
Phosphocreatin, 15; MgCl2, 1; CaCl2, 0.5; Mg-ATP, 3; Na-GTP, 0.5.  
2) NaCl, 10; CsMeSO4, 82; K-BAPTA, 11; HEPES, 10; KCl, 1, TEA-Cl, 15; 4-AP, 5;Qx-
314-Cl, 3.35; Phosphocreatin, 15; MgCl, 1; CaCl, 1; Mg-ATP, 3; Na-GTP, 0.5. This solution 
was used for experiments in which blocking of potassium channels was required. 
The electrode solutions were set to pH 7.25 (with KOH) and an osmolality of 295 mOsmol/l. 
Typical electrode resistance was 2-3 MΩ and the series resistance throughout recordings was 
in the range of 5-15 MΩ and regularly monitored during recordings. Electrophysiological 
experiments were governed by Pulse software (HEKA Elektronik, Lambrecht/Pfalz, 
Germany) operating on an IBM-compatible PC. Recorded current and voltage traces were 
corrected for liquid junction potential (Vm = Vp -10 mV; where Vm = membrane potential and 
Vp = potential of the pipette). Series resistance compensation of 25% was routinely used. 
The resting membrane potential (RMP) was assessed immediately after breaking the 
membrane patch, thus achieving the whole cell configuration, to avoid dilution of the intra-
cellular environment. The passive and active membrane properties were recorded under 
current clamp conditions by holding the cell at -65 mV and injecting hyperpolarizing and 
depolarizing currents (duration of 1s, amplitude from -100 pA till +240 pA, in 20 pA 
increments). The input resistance (Rin) was calculated from the voltage shift during a current 
injection of -60 pA. The cell capacitance (C) was calculated as C = τ/R and the τ (membrane 
time constant) was obtained by a monoexponential fit of the hyperpolarizing voltage-
deflection elicited by a -60 pA current–injection during the current clamp recordings. 
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4.4.3. Voltage-clamp analysis 
The changes in current amplitude were measured in the voltage clamp mode maintaining the 
same recording conditions and adding routinely: mibefradil (2 µM), ZD7228 (30µM) and 
TTX (0.5 µM) to the bath solution. The membrane potential was held at -65 mV and 
thereafter depolarized to -45 mV for 4 s, followed by a repolarization to -60 mV for 3 s. This 
protocol was chosen with respect to the slow activation and deactivation with the latter 
resulting in the typical M-channel tail current. This voltage step was preceded by a short 
depolarizing step (from -65 mV to -40 mV, 80 ms), a pre-pulse, which aims to inactivate fast 
transient membrane currents. The step protocol was repeated over time: during control 
conditions and during drug application. The amplitude of the current was analysed at the end 
(the last 500 ms) of the depolarizing voltage step, when the activation of M-current was 
maximal. Current amplitudes were compared under control conditions, in the presence of 
drugs and after washing out. The difference between the mean of the recordings at control 
conditions and in the presence of the drugs is termed drug-evoked current (also named 
sensitive current, in the following). The values are expressed in percent of control values 
(control = 100%). The visual representation of the sensitive current is obtained by subtraction 
of the current during drug application from the current under control conditions. 
The recordings to analyse the family of currents have been performed under voltage clamp 
conditions holding the membrane potential at -85 mV and applying hyperpolarizing and 
depolarizing steps lasting for 4 s starting from -65 mV to -25 mV with an increment of 15 
mV. The protocol is shown in Fig. 4 and it was preceded by the pre-pulse, it was repeated 
undero control conditions and in the presence of retigabine.  
A ramp protocol was used to establish the current-voltage relationship (I/V). The neuron was 
held at –35 mV to open the M-channels and ramped to –135 mV (100 ms) and re-polarised to 
holding potential. The change in the current is proportional to the change in the holding 
voltage (1 ms = 10 mV). Then, the value of the reversal potential of the senstive current was 
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obtained empirically and compared to the value calculated by application of Nernst’s 
equation, considering a temperature of 22-23 °C and the composition of the electrode 
solutions (K+ concentration of 108 mM). 
 
4.4.4. Current-clamp analysis 
The current clamp experiments were performed using the bath solution without blockers. 
Tonic firing was induced by current injection of four different amplitudes (50, 100, 150 and 
200 pA) lasting for 2.5 s when the cell was held at ~ -60 mV by the injection of a DC current. 
The bursting mode (bursts of action potentials crowning a low-threshold Ca2+-peak) was 
elicited by injecting 50 pA depolarizing steps from hyperpolarized potentials of ~ -65 mV. 
The number of action potential during tonic firing and burst was calculated using a custom-
made Matlab script (courtesy of Dr. Patrick Meuth). Neurons with a Vm more positive than – 
55 mV and non-overshooting action potentials were discarded. 
 
4.4.5. Drugs 
For pharmacological tests drugs were added to the external solution and all the concentrations 
herein reported are final concentrations. Linopirdine (10 µM), oxotremorine-M (10 µM), 
pirenzepine (10 µM), 4-DAMP (10 µM), carbachol (25 µM), DAMGO (1 µM), leu-
enkephalin (500 nM), nociceptin (1 µM), endomorphin-1 (1 µM) and dynorphin A (1 µM) 
were purchased from Tocris Bioscience, (Bristol, UK). ZD7288 (30 µM), mibefradil (2 µM), 
XE991 (20 µM), diclofenac (20 µM), meclofenamic acid (20 µM) were purchased from 
Abcam Biochemicals (Cambrige, UK). Nifedipine (1 µM) was purchased from Sigma 
(Taufkirchen, Germany); TTX (0.5 µM) was purchased from Biotrend (Cologne, Germany); 
retigabine (30 µM) was purchased by LGM Pharma (Boca Raton, Florida). ICA27243 (30 
µM) and maxipost (20 µM) were kindly provided by Dr. Dalby-Brown from Neurosearch 
(Ballerup, Denmark).  
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In case substances were dissolved in dimethylsulfoxide (DMSO), solvent concentration did 
not exceed 0.1%. The solvent alone had no effect on the investigated parameters. 
 
4.4.6. Cell culture transfection  
The experiments described in this paragraph have been conducted by the candidate in 
collaboration with Prof. Oliver’s group at the University of Marburg. Chinese hamster ovary 
(CHO) cells were maintained in MEM Alpha Medium (Invitrogen GmbH, Darmstadt, 
Germany) supplemented with 10% foetal calf serum (FCS) and 1% penicillin/streptomycin 
(both from Invitrogen). For experiments, cells were plated on glass cover slips (Carl Roth, 
Karlsruhe, Germany) and transfected with jetPEI transfection reagent (Polyplus Transfection, 
Illkirch, France). The transfection vectors were pBK-CMV containing human KCNQ2 
(NM_172106.1) and human KCNQ3 (NM_004519.2), and were expressed under the control 
of CMV promoter. The cells were co-transfected with pEGFP-C1 (Clontech, Saint-Germain-
en-Laye, France) to identify transfected cell. Plasmids coding for KCNQ2 and KCNQ3 
subunits were transfected at various concentration ratios while the total amount of the DNA 
was kept constant: KCNQ2/3 1:1, KCNQ2/3 9:1 and KCNQ2/3 1:9. Experiments on 
transfected cells were performed between 24 h and 48 h post-transfection. 
 
4.4.7. Patch-clamp recordings in CHO culture cells 
Patch clamp recordings were performed in the whole cell configuration with an Axopatch 
200B amplifier (Molecular Devices, Union City, CA). Data were sampled with an ITC-18 
interface (HEKA Elektronik, Lambrecht, Germany) governed by PatchMaster software 
(HEKA) via a Macintosh PowerPC (Apple Inc, Cupertino, CA, USA). Currents were low-
pass filtered at 2 kHz and sampled at 5 kHz, and whole-cell capacitance was compensated in 
the whole-cell configuration. Patch electrodes were pulled from borosilicate glass (Sutter 
Instruments Company, Novato, CA, USA) to an open pipette electrode resistance of 1.5-3 
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MΩ when back-filled with intracellular solution containing (in mM): 135 KCl, 2.41 CaCl2 
(0.1 µM free Ca2+), 3.5 MgCl2, 5 HEPES, 5 EGTA, 2.5 Na2ATP, pH 7.3 (with KOH), 290-
295 mOsm/kg. Series resistance (Rs) typically was below 8 MΩ and Rs compensation (80-
90%) was applied throughout the recordings. Access to the basolateral membrane of OHCs 
was achieved by gently removing surrounding tissue with a suction pipette. In transfected 
CHO cells the robust expression of KCNQ2 and KCNQ3 was verified by GFP fluorescence. 
All experiments were performed at room temperature (23°C). Membrane potentials shown 
were not corrected for liquid junction potentials (Vm = Vp - 4 mV; Leitner et al., 2012). 
 
4.4.8. Voltage-clamp analysis 
The protocol used during the experiments on CHO transfected cells is a series of 
hyperpolarizations and depolarization from -100 mV to + 40 mV with an increment of 10 mV 
(Vh = -60 mV; see Fig. 20). By calculating the difference between the current at the beginning 
of each step with the current at the end (steady state) on the same step the current-voltage 
relationship has been obtained. 
 
4.4.9. Reverse transcription RT-PCR assays 
Total RNA was prepared from freshly dissected tissue by extraction with Trizol reagent 
according to the manufacturer’s instructions (RNeasy Lipid Tissue, Qiagen, Hilden, 
Germany). First-strand cDNA was primed with random hexamer primers (Invitrogen Life 
Technologies) from 0.5-1 µg of RNA and synthesized using the SuperScript II enzyme 
(Invitrogen) at 42oC for 50 min. Normalization was carried out against an endogenous 
housekeeping gene transcript for β-actin. PCR was performed in a 20-µl reaction the mixture 
using 0.5 U Taq polymerase (Qiagen); mixture in all cases contained 1.5 mM MgCl2, 0.2 mM 
of each dNTP, and 20 pmol of each primer using the following cycling protocol: 3 min at 
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94°C; 35 cycles (25 cycles in case of β-actin): 30 s at 94°C, 1 min at 58oC, 1 min at 72°C; 
with a final elongation for 7 min at 72°C. 
The following primers were used: 
KCNQ1 (nucleotides 556-984), accession No. NM_008434 
for: GCCACCGGGACCCTCTTCTG 
rev: GATGCGGCCGGACTCGTTCA 
KCNQ2 (nucleotides 979-1500), accession No. NM_001003824 
for: CAAGTACCCTCAGACCTGGAAC 
rev: CAGCTCTTGGGCACCTTGCT 
KCNQ3 (nucleotides 1798-2265), accession No. NM_152923 
for: CCAAGGAATGAACCATATGTAGCC 
rev: CAGAAGAGTCAAGATGGGCAGGAC 
KCNQ4 (nucleotides 732-1085), accession No. NM_001081142 
for: CATCGGGTTCCTGGTGCTCATCTT 
rev: TAGGCCCGGCTTGTGTCCGTG 
KCNQ5 (nucleotides 984-1183), accession No. NM_001160139 
for: CCATTGTTCTCATCGCTTCA 
rev: TCCAATGTACCAGGCTGTGA 
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-actinβ (nucleotides 333-1160), accession No. NM_007393 
for: ATCTGGCACCACACCTTCTACAAT 
rev: CTGCTTGCTGATCCACATCTGC 
 
4.4.10. Immunofluorescence 
Mice (23-27 days old) were deeply anaesthetized using pentobarbital (50 mg/kg body weight) 
and transcardially perfused with PBS, followed by an ice-cold 4% PFA/PBS for 35–40 
minutes. Brains were removed, post-fixed overnight in 4% PFA/PBS and cryoprotected with 
25% sucrose. Coronal sections (40 µm) were cut at the level of the VB and collected in Tris-
buffered saline (TBS). After several washings with TBS, sections were blocked with 10% 
normal horse serum (NHS), 2% BSA, 0.3% Triton X-100 in TBS for 2 h to minimize 
nonspecific binding before incubation of slices with primary antibodies in 2% NHS, 2% BSA, 
0.3% Triton X-100 in TBS at 4 oC for 16-18 h. The following antibodies were used: rabbit 
anti-KCNQ2 or rabbit anti-KCNQ3 (1:500 for both, Alomone Labs, Jerusalem, Israel) and 
mouse anti-NeuN (1:200, Millipore). After washing (3 x 10 min with TBS), sections were 
exposed to Cy2-conjugated donkey anti-mouse and Cy3-conjugated donkey anti-rabbit IgG 
(1:300 for all, Dianova, Kerala, India) for 1.5 h, washed again and cover slipped with 
Immumount. For negative controls occlusion of the primary antibody from the staining 
procedure was routinely performed with no positive immunological signal detected. For 
additional negative controls pre-adsorption of the primary antibody using a control antigen 
was performed according to the manufacture’s instruction (Alomone Labs, Jerusalem, Israel). 
In brief, KCNQ2 (or KCNQ3) antibody was pre-incubated at its working dilution (see above) 
with corresponding control peptide antigen for 1 h. The antigen-antibody complexes were 
spun down by centrifugation, and the resulting supernatant was used in place of the primary 
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antibody. No staining was obtained by incubation with the pre-adsorbed serum. Pre-
adsorption procedure was specific and did not influence other primary antibody stainings.  
All images were obtained using confocal laser scanning microscope (Nikon eC1 plus, 
Duesseldorf, Germany). Densitometric analysis of immunofluorescence was performed by 
using the fluorescence measuring function of ImageJ software (public domain, National 
Institutes of Health). One hundred square areas (30 µm × 30 µm) were placed on different 
positions of VB images and the mean fluorescence intensity was determined after background 
subtraction. This analysis was repeated for three slices taken from different animals. 
 
4.5. In vivo experiments 
4.5.1. Surgery 
All animal work has been approved by local authorities (review board institution: Landesamt 
für Natur, Umwelt und Verbraucherschutz Nordrhein-Westfalen; approval ID numbers: 84-
02.04.2011.A177). 
C57Bl6J male mice (P30) were purchased from Charles River (Germany) and group-housed 
for one week in the animal facility in order to allow recovery from shipping stress. After 
recovery period, animals were individually housed for an additional week and later underwent 
the surgery. The animals were anaesthetized with i.p. (intra-perithoneal) injection of 
pentobarbital (50mg/kg) supplemented with a subcutaneous injection of analgesic agent 
Carprofen (25ml/kg; Rimadyl, Pfitzer GmbH, Berlin, Germany). Additionally, 10 minutes 
before the start of the surgery all tissues to be incised were injected with an analgesic agent 
(2% xylasine, Astra Zeneca GmbH, Wedel, Germany), all pressure points were covered with 
2% xylasine gel and corneas were protected with Bepanthen eye gel (Bayer, Leverkusen, 
Germany). Animals were mounted in the stereotaxic apparatus (ASI Instruments, Ins., Waren, 
MI, USA) via ear and incisor bars. The skin on the top the skull was incised, the soft tissue 
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covering the skull was removed and the levels of bregma and lambda were equalized in the 
horizontal plane. Holes in the skull were drilled bilaterally above VB complex according to 
stereotaxic coordinates obtained from Brain Atlas (Paxinos & Franklin, 2001) that were: 1.7 
mm posterior from bregma, 1.85 mm lateral from bregma and 3.3 mm ventral from the 
cortical surface. The left brain hemisphere was implanted with a custom made guide canula 
(12 mm long, ID = 250 µm, OD = 360 µm, Polymicro Technologies, Phoenix, AZ, USA), the 
right hemisphere was implanted with self made microelectrode array (eight recording 
electrodes) coupled with a second guide canula. Implants were secured in place with dental 
cement and animal was allowed to recover for at least four days before a hot plate tests was 
performed. 
 
4.5.2. Hot plate test 
The hot plate test was performed as previously described (Kuraishi et al., 1983). The hot plate 
apparatus herein used differs from the ones available on the market because of an additional 
sliding Plexiglas platform parallel to the plate. The platform creates the floor of the testing 
cylinder and was designed such that placing and removal of the animal from the plate was 
possible without delay and without causing damage to the injection system mounted on the 
animal’s head. In fact, this was necessary since animals were connected, via injection canula 
(1m long, ID = 40 µm, OD = 150 µm, Polymicro Technologies, USA) to the Hamilton syringe 
for the intra-thalamic injection and via cable to the amplifier for electrophysiological 
recordings. Both syringe and amplifier cable were connected to a swivel in order to avoid any 
restriction movements. The temperature of the plate was set at 55 ± 1 °C. The latency was 
defined as the time elapsed from the placements of the animal on the plate until the time when 
the first pain behaviour was noticed. The following behaviours were considered as signs of 
pain: jumping, paws licking or shaking (Crockett et al., 1977). To prevent any skin damage of 
the animal’s paws, after a maximum of 20 s the animal was removed (cut off time). Every 
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animal was subjected the test twice, before and after drug injection (volume = 300 nl/site, 
speed 100 nl/min). The interval between the injection and the second trial depended on the 
administered drug and was: 60 min for retigabine (3 mM, 300 nl) and DMSO (0.1% in 0.9% 
NaCl); 40 min for XE991 (2 mM, 300 nl); 10 min for muscimol (0.3 nM, 300 nl) and 
DAMGO (1 µM, 300 nl); 30 min for β-endorphin (0.2 nM, 30 nl). The interval time 
corresponded to the time taken to achieve maximum analgesic effects, as has been assessed 
experimentally. 
 
4.5.3. Histological verification of injection sites 
All injected solutions contained the fluorescent dye Alexa-488 in order to mark the injection 
site. At the end of the experiment, the animals were given an overdose of isoflurane and were 
decapitated. The brain was quickly removed, placed in buffered 4% paraformaldehyde (PFA) 
for eight hours and then transferred to cryoprotective solution containing 30% sucrose for 12 
h. Subsequently, 50 µm thick coronal slices containing the VB were cut, mounted on glass 
slides and inspected for fluorescence with 10× objective of a confocal microscope (Fluoview 
300, Olympus, Hamburg, Germany). For documentation digital photographs were taken. Only 
animals in which the injection sites were verified to be correct in both hemispheres were 
considered for further statistical analysis. 
 
4.5.4. Physiological release of β-endorphins 
To assess the possible role of β-endorphin as an endogenous KCNQ channel modulator, a 
protocol to induce the physiological release of β-endorphin was developed. In our protocol we 
combined physical exercise and the ingestion of sweet palatable food because both conditions 
have been shown to induce β-endorphin release in mice and rats (Werme et al., 2000; Dum et 
al., 1983; Takeda et al., 2000; Mizushige et al., 2006). The animals underwent 7 training 
sessions (one/day) consisting of 20 min running in a running wheel (TSE Systems GmbH, 
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Berlin, Germany) followed by receiving highly palatable food like chocolate milk (low fat 
milk with 6% chocolate powder, Nesquick, Nestlè, France) and pieces of chocolate-covered 
waffles (Kit-Kat, minimal chocolate content 27%, Rowntree Macintosh GmbH, Hamburg, 
Germany). Training was conducted in the evenings, when rodents are naturally active. For 
every animal, the total wheel rotations were counted and the total distance covered in 20 
minutes was calculated (wheel diameter = 12 cm). At the end of the last training session (i.e. 
at the end of the 7th day) the animals were subjected to hot plate test and sacrificed directly 
after. The brains and blood of three animals were used for the quantification of β-endorphin 
content with the ELISA test and the brains of the other two remaining animals were used for 
the ex vivo electrophysiological recordings. 
 
4.5.5. Enzyme Linked Immuno-Absorbent Assay (ELISA) 
For the quantification of β-endorphin levels the 96 wells ELISA-EIA kit for mouse was used 
(Phoenix Pharmaceuticals, Inc., Karlsruhe, Germany). Immediately after the hot plate test, the 
animals were sacrificed, blood was collected in plastic tubes containing anti-coagulant 
(heparin or EDTA) and the brain was quickly dissected, collecting separately thalamus, 
hippocampus and cerebellum. To separate the plasma, blood was immediately centrifuged at 
1600 rpm for 15 minutes at 4°C and subsequently stored at -80 °C till the day of extraction. 
The brain tissue was homogenised in 5ml/g lysis buffer (10 mM Tris, pH 7.0), centrifuged at 
1600 rpm for 15 minutes at 4°C, the supernatant was collected and kept at -80°C till the day 
of extraction. The ELISA kit has a high sensitivity (Minimum Detectable Concentration = 
0.15 ng/ml), a necessary criterion for our purposes, because of the small amount of tissue. The 
extraction of endorphins was performed as described before (Hofbauer et al., 2000) and the 
Absorbance (A) value for every sample was obtained using a standard reader. To convert the 
absorbance values in ng (nano grams), these values were plotted in a semi logarithmic 
sigmoid curve obtained from the concentrations of a known protein (control curve, included 
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in the ELISA Kit). Thus, the values empirically calculated were referred to the total amount 
of tissue collected before the extraction and expressed in ng/mg for the tissue and in ng/ml for 
the plasma. 
 
4.5.6. Statistics 
All results were presented as mean ± SEM. Statistical significance of the data with Gauss 
distribution was evaluated by Student’s t-test. Multiple comparisons were done by ANOVA 
or Repeated Mesures ANOVA. For current-clamp data, custom written MatLab routines were 
used to analyze AP characteristics during burst and tonic firing. OriginPro software (version 
(8G, OriginLab, Friedrichsdorf, Germany), Statistica (Statsoft, Hamburg, Germany) and 
Prism (version 5, GraphPad software, San Diego, USA) were used for data analysis and figure 
plotting. 
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5. Results 
Electrophysiological characteristics of KCNQ channels in thalamocortical (TC) neurons of 
the ventrobasal complex (VB) were recorded using the patch clamp method in acute brain 
slices. Based on the recordings from 50 cells passive properties of the membrane were 
estimated and were: the resting membrane potential (RMP) was –65.8 ± 1 mV, input 
resistance (Rin) = 221.9 ± 26.6 MΩ and capacitance (Cs) value was 81.7 ± 4.5 pF and it 
remained stable during the recordings. The application of retigabine and XE991 hyperpolarize 
and depolarize the cell, respectively, but in general, drug application did not significantly 
change the RMP and the Rin values. 
 
5.1. M-current in TC neurons 
KCNQ channels are known to be activated by slow depolarizing stimuli (Brown et al., 1982). 
In order to assess in which conditions an outward current resembling M-current can be voked, 
the firts step of our experiment it was the analysis of a family of outward currents. The 
experiment was performed in VB TC neurons, in voltage clamp mode using the procol shown 
in Fig. 4. It consists of a series of slow depolarizing steps from -65 mV till -25 mV (Vh = -85 
mV). For every voltage step the correpsponding evoked current with a certain amplitude and 
kinetics can be observed. The recordings were performed under control conditions, in the 
presence of retigabine and/or XE991 to assess which was their effect on the evoked outaward 
currents (Fig. 4A, B and C). The calculated sensitive currents shown in Fig. 4D and E 
reveleaded typical kinetics for an M-current-like at positive more positive than -55 mV. 
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In the following experiments, changes in the current amplitude were measured from VB TC 
neurons in voltage clamp mode using the protocol shown in Fig. 5. The membrane potential 
was held at -65 mV (a value resembling the RMP of a VB TC neuron), thereafter depolarized 
to -45 mV for 4 s and followed with hyperpolarization to -60 mV for 3 s. To verify that the 
M-current in VB TC neurons is mediated by KCNQ2 and KCNQ3 channels, during 
electrophysiological recordings a specific channel opener retigabine (30µM) as well as 
specific blockers XE991 (20µM) and linopirdine (10µM) were applied.  
The application of retigabine facilitated the opening of the KCNQ-channels, inducing an M-
current (Fig. 5A). The calculated retigabine-sensitive current (Fig. 5B, obtained by 
subtraction of the current recorded during retigabine application from the current recorded 
under control conditions) revealed well known M-current characteristics: slow activation and 
slow deactivation, the latter visible in the tail currents. The effect of retigabine on the current 
amplitude was almost completely prevented by co-administration of XE991 or linopirdine 
(control, 100 ± 12.8 %; retigabine, 171.2 ± 23.6 %; retigabine + XE991, 102.9 ± 16.4 %; 
retigabine + linopirdine, 107.3 ± 8 %, Fig. 5C). The application of XE991 alone reduced the 
Fig. 4. M-current is activated by positive voltage steps in the presence of retigabine. The upper panel 
shows the evoked currents, in VC mode, in response to increasing depolarizing voltage steps from -65 mV to 
-25 mV, under control conditions, after application of retigabine and in retigabine + XE991 (A, B and C, 
respectively). The calculated sensitive currents in E and D show the M-current like kinetics at positive 
potential, in the presence of retigabine. 
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current amplitude, indicating open M-channels at RMP conditions. A competitive effect 
between retigabine and XE991 was observed during co-administration of both compounds 
while the pre-incubation with XE991 prevent channels activation (73.4 ± 18.9 %, Fig.1C; 
Repeated Measures ANOVA, F (4, 31) = 4.57; p = 0.0051; Newman-Keuls post-hoc test: 
retigabine vs. control: #p < 0.05; retigabine + XE991 and + linopirdine vs. retigabine: *p < 
0.05; XE991 vs. retigabine: **p < 0.01; n = 7; Fig. 5C). 
 
 
 
 
Fig. 5. Retigabine activates M-current in TC neurons. The application of retigabine (30 µM) induces M-
current as shown in the example traces in A while the sensitive current reveals the slow activation and 
deactivation kinetics (B). The bar graph in C shows a significant increase in the current amplitude due to the 
application of retigabine alone compared to control conditions (retigabine vs. control: #p < 0.05). Moreover, 
retigabine application in combination with different M-channel blockers (XE991, 20 µM; linopirdine, 10 
µM) and the application of XE991 alone induce significantly smaller effects (retigabine + XE991 and + Lino 
vs. retigabine: *p < 0.05; XE991 vs. retigabine **p < 0.01; n = 7). 
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5.2. M-channels regulate cell excitability in TC neurons 
Next, electrophysiological experiments were performed in the current-clamp mode to assess 
that M-channels are involved in regulation of cell excitability and shape tonic and burst firing 
modes which are characteristic for TC neurons (Steriade et al., 1988). Tonic firing was 
evoked by injection of direct current steps of four different amplitudes (50, 100, 150 and 200 
pA) while the cell was held at ~-60 mV. The application of retigabine during evoked tonic 
firing, slightly hyperpolarized the cell and significantly reduced the number of action 
potentials when compared to control conditions (Fig. 6C) and shifting the firing pattern to 
burst-like activity (Figs. 6A and B; Repeated Measures ANOVA, F (7, 71) = 2.3; *p = 0.0322; 
Newman-Keuls post-hoc test: *p < 0.05 vs. respective controls; n = 11/4; Fig. 6C). On the 
other hand, XE991 slightly depolarized the cell and augmented the number of action 
potentials (Figs. 7A, B) with a significant effect due to the treatment (Repeated Measures 
ANOVA; F (5, 41) = 9.5; p < 0.001.; Newman-Keuls post-hoc test: ns; n = 7/3, Fig. 7C). 
 
 
                                                                                                                                                                         Results 
 41 
 
 
Fig. 6. M-channel enhancement reduces tonic firing. In A and B example traces recorded from VB TC 
neurons show a firing pattern that was induced by a depolarizing pulse (200 pA of 2.5 of duration). ACSF 
without (A) and with retigabine (B) was used. The bar graph shows the effects of drug application on the 
number of action potentials during control conditions (white bars) and in the presence of retigabine (filled 
bars, C) during the respective current injections (*p < 0.05 vs. respective control; n = 11/4). 
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5.3. Effect of M-channel modulation on burst firing 
From more hyperpolarized potentials (> -60 mV), injection of 50 pA depolarizing steps 
elicited bursts of action potentials crowning a low-threshold Ca2+ spike. The application of 
both retigabine and XE991 influenced the number of action potentials in a burst (Fig. 8A-D). 
Application of retigabine induced a decrease in the number of burst action potentials (control, 
4.1 ± 0.49; retigabine, 2.2 ± 0.42; paired t-test, t = 3.6; ***p= 0.0048; n=13/3) while XE991 
significantly increased that number (control, 3.3 ± 0.66; XE991, 5.2 ± 0.55; paired t-test, t = 
4.8; ***p = 0.0004; n = 11/3).  
Fig. 7. M-channel inhibition increases cell excitability. In A and B example traces recorded from VB TC 
neurons show a firing pattern that was induced by a depolarizing pulse (200 pA of 2.5 of duration). ACSF 
without (A) and with XE991 (B) was used. The bar graph shows the effects of drug application on the 
number of action potentials during control conditions (white bars) and in the presence of XE991 (filled bars, 
C) during the respective current injections (general effect of the treatment p < 0.001; n = 7/3). 
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5.4. Muscarinic modulation of M-channels 
Since M-channels were first identified as K+ channels that are sensitive to muscarinic 
compounds (Marrion, 1989), a set of experiments using muscarinic agonists and antagonists 
has been performed. 
Fig. 8. M-channel modulation influences the burst firing in TC neurons. Example traces showing burst 
firing before (A, C) and after application of XE991 (B) and retigabine (D) in TC neurons (holding potential: 
~-65 mV, depolarizing step: 50 pA). The insets Aa-Dd show bursts at higher temporal resolution (retigabine 
paired t-test, t = 3.6; ***p = 0.005; n = 11; XE991; paired t-test, t = 4.8, ***p = 0.0004; n = 13; E and F). 
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Oxotremorine M (Oxo-M). The muscarinic agonist oxotremorine-M (Oxo-M, 10 µM) was 
tested during recordings in VC mode using the protocol shown in the inset of Fig 5. 
Activation of muscarinic receptors (MAChR) by Oxo-M inhibited M-channels and reduced 
the amplitude of the retigabine-evoked current (Fig. 9; control, 100 ± 8.6 %; retigabine 147.4 
± 19.5 %; retigabine + Oxo-M, 123.7 ± 16.9 %). The application of XE991 in combination 
with Oxo-M completely reversed the effect of retigabine, reducing the current to control 
values (100.7 ± 9.9%; Repeated Measures ANOVA, F (3, 15) = 9.24; p<0.0001; Newman-
Keuls post-hoc test: retigabine vs. control #p < 0.05; retigabine + Oxo-M vs. retigabine *p < 
0.05; retigabine + Oxo-M + XE991 vs. retigabine **p < 0.01; n = 6/2).  
 
 
 
Carbachol. Carbachol (CChol) is a cholino-mimetic compound able to activate MAChR with 
less specificity than Oxo-M. The experiments in VC mode were performed as described 
above (see Fig. 9). The M-current evoked by application of retigabine was inhibited by the 
application of CChol (25µM; control, 100 ± 9 %; retigabine 154 ± 13.1 %; retigabine + 
CChol, 122 ± 15.9 %). The co-application of CChol and XE991 completely reverted the effect 
Fig. 9. M-current is inhibited by Oxo-M. The bar graph shows the changes in current amplitudes as 
consequence of respective drug application. The application of retigabine significantly increases the current 
amplitude while the co-applications with the muscarinic agonist Oxo-M and the specific KCNQ channel 
blocker XE991 significantly decrease the evoked current (retigabine vs. control #p < 0.05; retigabine + Oxo-
M vs. retigabine *p < 0.05; retigabine + Oxo-M + XE991 vs. retigabine **p < 0.01; n = 6/2).  
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induced by retigabine (88 ± 16.8 %; Repeated Measures ANOVA, F (3, 31) = 15.54; p < 
0.0001; Newman-Keuls post-hoc test: control vs. retigabine: ###p< 0.001; retigabine + CChol 
vs. retigabine: **p < 0.01; retigabine + CChol + XE991 vs. retigabine: *p< 0.05; n = 8/4; Fig. 
10).  
 
 
Muscarinic antagonists. Next, two subtype-specific muscarinic antagonists (pirenzepine for 
M1 and 4-DAMP for M3, 10 µM) were tested to assess if AChR inhibition affected the M-
current amplitude. Both compounds showed a weak effect when applied in the presence of 
retigabine (control, 100 ± 13.7 %; retigabine, 189.4 ± 21.8 %; retigabine + pirenzepine + 4-
DAMP, 198 ± 23.6 %, Fig. 11A). The co-application of Oxo-M and the muscarinic 
antagonists slightly reduced the M-current but, the effect was not significant (186 ± 21.5 %, 
Fig. 11A). The application of a drug cocktail containing additionally XE991 had stronger 
effect (data not shown; Repeated Measures ANOVA, F (3, 30) = 36.37; p < 0.001; Newman-
Keuls post-hoc test: retigabine and retigabine + pir. + 4-DAMP vs. control: ###p < 0.001; n = 
11/4). No effect of the two muscarinic antagonists was observed when the compounds were 
applied before retigabine (control, 100 ± 17.2 %; Pir + 4-DAMP, 100.2 ± 16.2 %; retigabine + 
Fig. 10. M-current is inhibited by carbachol. The bar graph shows the changes in current amplitude as 
consequence of respective drug application. The application of retigabine significantly increases the current 
amplitude, while co-applications with the muscarinic agonist CChol and the specific M-channel blocker 
XE991 significantly decrease the evoked current (regabine vs. control: ###p < 0.001; retigabine + CChol vs. 
retigabine: **p < 0.01; retigabine + Oxo-M + XE991 vs. retigabine: *p < 0.05; n = 6/2). 
                                                                                                                                                                         Results 
 46 
pir + 4-DAMP, 180.2 ± 28 %; Repeated Measures ANOVA, F (2, 23) = 13.36, p < 0.0001; 
Newman post-hoc test: Pir + 4-DAMP + retigabine vs. control: ##p < 0.001; Pir. + 4-DAMP 
vs. retigabine + Pir. + 4-DAMP: **p < 0.01; n = 8/2; Fig. 11B). 
  
 
5.5. The reversal potential of the current induced by retigabine and mediated by 
KCNQ channels 
In order to confirm that the current evoked by retigabine is carried by K+ ions, the current-
voltage relationship (I/V) was analysed and the reversal potential of the M-current was 
calculated. The following ramp protocol was used: the cell was held at -35 mV, and then it 
was hyperpolarized rapidly, in a ramp-like manner, (10 ms) to -135 mV and subsequently re-
polarized to –35 mV. Only open and non de-inactivating channels can follow this protocol: 
holding the cell at -35 mV keeps the KCNQ channels open and the changes in the voltage 
induce changes in the conductance of the channels and consequently, in the mediated current. 
The retigabine-sensitive current was obtained by graphical substraction and the resulting I/V 
Fig. 11. Block of M1/M3 AChR prevents the effect of Oxo-M but not retigabine. The application of the 
two M1/M3 AChR antagonists slightly increased the retigabine-activated current (retigabine + Pir + 4-
DAMP vs. control: ###p < 0.001; n = 11/4, A). The application of both muscarinic antagonists alone fails to 
induce an M-current, but this is successfully achieved by co-application of retigabine (Pir + 4-DAMP + 
retigabine vs. control: ##p < 0.001; Pir + 4-DAMP vs. retigabine + Pir + 4-DAMP: **p < 0.01; n = 8/2; B). 
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curve reversed at a potential of -98 ± 2 mV (~ 22 °C, n = 5; Fig. 12) which is close to EK (-
103 mV under the present recording conditions). 
 
 
5.6. M-channel modulation in VB TC neurons is not influenced by Ca2+ currents 
It has been shown that the activation of KCNQ channels can be modulated by changes of the 
intra- and extra-cellular Ca2+ concentrations (Hernandez et al., 2008) and that retigabine has a 
weak effect on activation of Ca2+ channels (Rundfeldt et al., 2000). Since the activation 
protocol for M-current can activate also fast-transient Ca2+ currents (T-type Ca2+ current), in 
all VC experiments, a preceding short depolarizing pulse was applied, that completely 
inactivated T-type Ca2+ current (Budde et al. 1992,; Fig. 13A, inset). Moreover, retigabine had 
no effect on the pre-pulse sensitive current (Fig. 13A). To further determine the specificity of 
the retigabine effect we isolated the Ca2+ current by blocking all K+ and Na+ currents using an 
intra-cellular solution containing CsMeSO4 (substitute of K+ inside the cell) and with several 
K+ and Na+ channel blockers. Under these conditions, retigabine had no effect on the recorded 
currents indicating that retigabine modulates K+ channels but not Ca2+ currents (Fig. 13B). 
Fig. 12. The reversal potential of the current mediated by KCNQ channels. A shows examples of the fast 
ramp protocols under control conditions (black trace), during retigabine and XE991 application (light and 
dark grey, respectively). The retigabine-senstitive current obtained as described before (see Material and 
Methods), shows a reversal potential very close to the EK (-98.2 mV, B). 
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5.7. Modulation of M-channels by endogenous compounds 
To identify possible endogenous agonists or modulator of M-channels in the VB, a series of 
experiments was performed using bath application of endogenously released substances or 
their exogenous derivatives. 
 
The opioid dynorphin A (Dyn A) has been shown to enhance M-current in the hippocampus 
(Tatulian et al., 2003). Experiments were performed in VC mode and three different 
concentrations of Dyn A (250 nM, 500 nM and 1 µM) were used. Only Dyn A at 1 µM 
concentration was able to evoke an XE991-sensitive response in 3 out of 25 neurons recorded 
(control, 100 ± 47.8 %; Dyn A, 118 ± 43.9 %; Dyn A + XE991, 107 ± 40.8 %, values were 
calculated for responding cells; Fig. 14A). However, effects were not significant. 
Fig. 13. Retigabine exerts no effect on Ca2+ currents. In the recording protocols used in this study, the VC 
step for the activation of M-channels is preceded by a pre-pulse which is a short depolarizing step (-45 mV 
for 80 ms) that inactivates transient currents. In A a magnification of the pre-pulse evoked current is shown. 
Current traces in the presence and absence of retigabine are shown. B shows example traces of VC 
recordings performed with CsMeSO3 in the presence (black) and absence of retigabine (red). 
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The sensitive current did not reveal the typical slow kinetics of M-current. Example traces 
recorded from a responding cell are shown in Fig. 14 Ba and Bb respectively. In current 
clamp experiments, the application of Dyn A (1 µM) increased the number of action 
potentials during tonic firing when a current step of 100 pA was injected into the cell (control, 
9 ± 1.9; Dyn A, 21 ± 8.5) although the RMP remained stable through all the experiment (-67 
± 1 mV before and -66 ± 0.2 mV after Dyn A application; data not shown). 
 
 
 
Since the κ-opioid receptor agonist Dyn A did not modulate the M-current, opioid agonists 
with different receptor specificity were probed in the following: 
 
DAMGO. We tested an analogue of morphine DAMGO ([D-Ala2, N-MePhe4, Gly-ol]-
enkephalin), a synthetic peptide with high affinity for µ- and δ−opioid receptors. In VC 
experiments DAMGO did not affect the outward current (n = 3/1), while in CC experiments it 
remarkably reduced the number of action potentials (upon injection of 100 pA current steps) 
compared to control conditions (n = 3/1; 9.0 ± 1.9 and 5.0 ± 3.0, respectively). The RMP was 
Fig. 14. Dynorphin A does not modulate M-channels. The application of dynorphin A fails to activate M-
current in 22 out of 25 recorded cells. The bar graph summarizes the effect of the three responding cells 
during control conditions, after application of Dyn A and during co-application with XE991 (A) as shown in 
the example traces and the dynorphin sensitive current in Ba and Bb, respectively. 
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slightly hyperpolarized compared to baseline (-67 ± 1 mV and -69 ± 1 mV, respectively; data 
not shown). 
 
Endomorphin-1. The application of endomorphin-1 (1 µM), which specifically binds to µ-
opioid receptors and is involved in arousal, induced no effect on the outward current in VC as 
well as in CC experiments (n=5/2; data not shown). 
 
Leu-Enkephalin. The enkephalins (Leu- and Met-Enkephalin) constitute an opioid family 
with a high affinity for µ- and δ−opioid receptors, but not for κ−receptors. In VC recordings, 
the application of Leu-Enkephalin (Leu-Enk, 500 nM) augmented an M-like current in 5 out 
of 22 TC neurons, and the co-application of XE991 reversed the evoked effect (control, 100 ± 
15.4 %; Leu-Enk, 111 ± 13.4; Leu-Enk + XE991, 96 ± 13.7; Repeated Measures ANOVA, F 
(2, 14) = 11.04, p = 0.005; Newman-Keuls post-hoc test: Leu-Enk vs. Control, #p < 0.05; Leu-
Enk + XE991, *p < 0.01; n = 5/5; Fig. 15A). The example traces depicted in Fig. 14Ba reveals 
slow kinetics of the Leu-Enk sensitive current. 
 In CC experiments Leu-Enk increased the number of action potentials in comparison to the 
control, upon injection of 50, 100 and 150 pA current steps (Fig. 15C; respectively for 
different amplitudes of the current steps: control, 1 ± 1; 26 ± 10.6; 15 ± 9; Leu-Enk, 8 ± 4.2; 
57 ± 19.6; 23 ± 14; Repeated Measures ANOVA, F (5, 27) = 3.145; p = ns; n = 6/2). 
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β-endorphin. The endogenous β-endorphin belongs to the opioid family although it does not 
bind to any of the opioid receptors. It is synthesized and released in the brain as well as in the 
blood stream after physical activity, strong trauma, stress and pain (Dum et al., 1983; Werme 
et al., 2000). Because of the role it plays in pain sensation (Stanojevic et al., 2007), β-
endorphin was here tested as a plausible M-channel modulator. In VB TC neurons, the 
application of β-endorphin (1 nM) during VC recordings augmented he outward current and 
the effect was reversed by co-application of XE991 (control, 100 ± 16.1 %; β-endorphin, 114 
± 16.8 %; β-endorphin + XE991, 74 ± 15 %; Repeated Measures ANOVA, F (2, 11) = 3.3; p 
Fig. 15. Leu-enkephalin augments M-like current in some TC neurons. The application of Leu-
Enkephalin (500 nM) to VB TC neurons significantly increases the outward current. This effect can be 
reversed by co-application with XE991 (Leu-Enk vs. Control, #p < 0.05; Leu-Enk + XE991, *p < 0.01; n = 
5/5; A). The example traces (a) and the sensitive current (b) are shown in B. The application of the same 
drug in CC experiments (C) increases the number of action potentials when current steps of 50, 100 and 150 
pA are injected into the cell (n = 6/2). 
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= 0.107; n = 5/3; Fig. 16A). The positive effect of β-endorphin was recorded in 5 out of 12 
neurons. In the example traces and the calculated sensitive current shown in Fig. 16Ba and Bb 
an M-like current kinetics can be seen. 
 
 
 
Nociceptin. Several studies linked the peptide nociceptin to pain sensation and to the 
modulation of M-channels (for review see Meis et al., 2003). To assess a similar link, in VB 
TC neurons, nociceptin (1 µM) was applied in VC experiments. Application of nociceptin 
augmented the depolarization-induced current. The effect was reversed by co-application of 
XE991 (control, 100 ± 15.9 %; nociceptin, 119 ± 13.3 %; nociceptin + XE991, 93 ± 14 %; 
Repeated Measures ANOVA, F (2, 17) = 16.13, p = 0.0007; Newman-Keuls post-hoc test: 
nociceptin vs. control ##p < 0.01; nociceptin + XE991 vs. nociceptin **p < 0.01; n = 6/1; Fig. 
17A). However, the nociceptin-sensitive component of the current (Fig. 17Bb) did not show 
the typical M-current kinetics (slow activation and de-activation) suggesting the contribution 
of other K+ currents. To clarify this issue, we first blocked M-channels with the specific 
blocker XE991 (20 µM) and then applied nociceptin, under this conditions, nociceptin still 
Fig. 16.  β-endorphin increases M-like current in TC neurons. β-endorphin in VB TC neurons nominally 
increases M-like current (A) inducing an effect that can be reversed by co-application of XE991 (p = 0.107; n 
= 5/3). In B the example traces (a) and the sensitive current (b) show the typical slow activation and de-
activation of M-current. 
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evoked a K+ current increase (control, 100 ± 8.2 %; XE991, 86.1 ± 21 %; nociceptin + 
XE991, 101 ± 22 %; Repeated Measures ANOVA, F (2, 11) = 2.74, p = 0.142; n = 4/1; Fig. 
17C). In an additional set of experiments, M-channels were activated with retigabine and 
subsequently nociceptin was applied. In this case, we observed the typical augmentation of 
the current due to retigabine and a further increase by nociceptin (control, 100 ± 10.9 %, 
retigabine, 138 ± 25.4 %; nociceptin + retigabine, 166 ± 36.6 %; Repeated Measures 
ANOVA, F (2, 11) = 2.48, p = 0.163; n = 4/1; Fig. 17D). Taken together, nociceptin activated 
an outward current with only little XE991-sensitivity. 
  
 
 
Fig. 17. Effect of nociceptin on the outward current. Nociceptin increases the outward current (##p < 0.01), 
and the effect was reversed by co-application of XE991 (20 µM; **p < 0.01; A). The same experiment has 
been conducted applying nociceptin in the presence of XE991 (C) and in the presence of retigabine (D), in 
both cases nociceptin elicits an effect on the outward current.  
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5.8. Novel synthetic compounds can modulate M-channels 
Further experiments to prove the nature of the M-channels in TC neurons of the VB were 
performed using the synthetic compounds ICA27243 and maxipost (kindly provided by Dr. 
Dalby-Drown, Neurosearch, Copenhagen, Denmark). 
 
ICA27243. ICA27243 (30µM) is a specific opener for heteromeric M-channels composed of 
KCNQ2 and KCNQ3 (Wickenden et al., 2008). Its application increased an M-like current in 
VC experiments and the effect could be reversed by co-application of XE991 (control, 100 ± 
21.3 %; ICA25243, 115.2 ± 22.7 %; ICA25243 + XE991, 99.1 ± 20.4%; Repeated Measures 
ANOVA, F(2,12) = 9.39, p=0.0035; Newman-Keuls post-hoc test: ICA25243 vs. control: 
##p< 0.01; ICA25243 + XE991 vs. ICA27243: **p< 0.01; n = 7/2; Fig. 18A). A further proof 
of the specificity of the effect induced by this substance is given by applying ICA27243 after 
blocking M-channels with XE991. Under these conditions, ICA27243 failed to evoke an 
increase of the current (Fig. 18C). Example traces and the calculated ICA27243-sensitive 
current showed the slow activation typical for M-current (Fig. 18Ba and Bb, respectively). 
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Maxipost. The molecule BMS204352, also named maxipost, is an opener preferring KCNQ4 
and KCNQ5 subunits (Schroder et al., 2001; Dupuis et al., 2002). This substance therefore 
allowed evaluating the contribution of KCNQ4 and KCNQ5 subunits to the assembled M-
channels in VB. Application of maxipost (20 µM) induced an increase of M-current and the 
extent of this increase was similar to the one induced by ICA27243 application. The effect 
was reversed by application of XE991 (control, 100 ± 10.5 %; maxipost, 117.3 ± 11.6 %; 
maxipost + XE991, 97.9 ± 9.6 %; Repeated Measures ANOVA, F (2, 6) = 18.09; p = 0.0029; 
Newman-Keuls post-hoc test: maxipost vs. control: ##p<0.0; maxipost + XE991 vs. maxipost: 
Fig. 18. ICA27243 positively modulates M-channels. The current amplitude recorded during the 
application of the M-channel modulator ICA25243 and the effect of the co-application of XE991is shown (A; 
ICA25243 vs. control: ##p< 0.01; ICA25243 + XE991 vs. ICA27243: **p< 0.01; n = 7/2). Example traces in 
Ba and the ICA25243-sensitive current in Bb show the characteristic kinetics of an M-current. The bar graph 
in C shows that the ICA27243 effect was nearly prevented in the presence of XE991. 
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**p < 0.01; n = 4/1; Fig. 19A). The example traces (Fig. 19Ba) and the sensitive current 
evoked by maxipost (Fig. 19Bb) show the typical M-current kinetics. 
 
 
 
5.9. Anti-inflammatory drugs modulate M-channels 
Diclofenac and meclofenamic acid are non-steroid anti-inflammatory drugs used in the 
treatment of pain. The mechanism of action is a specific inhibition of cyclooxigenase II (Cox 
II) and prostaglandin synthesis (PG), involved in the inflammatory response triggered by 
noxious stimuli. Thus, diclofenac and meclofenamic acid exhibit analgesic and anti-
inflammatory effect (Menassè et al., 1978). Additionally, they have been found to modulate 
KCNQ channels in primary cell cultures (Peretz et al., 2005). 
 
Diclofenac. The application of diclofenac (20 µM) induced significant enhancement of M-
current and this effect was sensitive to XE991 (control, 100 ± 14.6 %; diclofenac, 132.6 ± 
17.5 %; diclofenac + XE991, 93.9 ± 11.9 %; Repeated Measures ANOVA, F (2, 16) = 14.8, p 
= 0.0002; Newman-Keuls post-hoc test: diclofenac vs. control: ##p < 0.01; diclofenac + 
XE991 vs. diclofenac: **p < 0.001; n = 9/3; Fig. 20A). The example traces and the calculated 
Fig. 19. Maxipost positively modulates M-channels. The application of the specific M-channel modulator 
maxipost increases M-current in TC VB neurons (A). The effect is reversed by co-application of XE991 
(maxipost vs. control: ##p<0.01 M; maxipost + XE991 vs. maxipost: **p < 0.01; n = 4/1, A). B) An example 
trace is shown in a and the maxipost-sensitive component of the outward current is shown in b. 
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diclofenac-sensitive current show slow activation and deactivation, typical M-current 
characteristics (Fig. 20Ba and Bb, respectively). Further evidence supporting the specificity of 
diclofenac activation of M-current is shown in Fig. 20C, when M-current is blocked by 
XE991, diclofenac fails to induce any increase in the evoked current amplitude. 
 
 
 
Meclofenamic acid. Meclofenamic acid (20µM) increased M-current to a similar extent as 
diclofenac. The co-application with XE991 reverted this effect further confirming specific 
action on M-current (control, 100 ± 13.2 %; meclofenamic acid, 125.6 ± 10.2 %; 
Fig. 20. Diclofenac augments M-current in VB TC neurons. The bar graph in A shows the current 
amplitude under control conditions and in the presence of the anti-inflammatory drug diclofenac. The 
diclofenac effect can be reversed by prior co-application of XE991 (diclofenac vs. control: ##p < 0.01; 
diclofenac + XE991 vs. diclofenac: **p<0.001; n = 9/3). In C the prior application of XE991 almost prevent 
the dcilofenac effect. The example traces (Ba) and the calculated diclofenac-sensitive current (Bb) show the 
slow activation and deactivation kinetics typical for M-current.  
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meclofenamic acid ± 7.95 %; Repeated Measures ANOVA, F (2, 6) = 11.32, p= 0.0092; 
Newman-Keuls post-hoc test: meclofemanic acid vs. control: ##p < 0.01; meclofenamic acid + 
XE991 vs. meclofenamic acid: *p < 0.05; n = 4/3; Fig. 21). However, the kinetics of 
activation and deactivation did not exhibit the slow time course of the M-current (Fig. 21Ba 
and Bb). 
 
 
 
Fig. 21. Meclofenamic acid modulates M-channels in TC neurons. The application of the anti-
inflammatory compound meclofenamic acid significantly increases the current amplitude (A), and the co-
application of XE991 reversed this effect (##p < 0.01 meclofenanic acid vs. control, *p < 0.05 meclofenamic 
acid + XE991 vs. meclofenamic acid; n= 4/3). Example traces and the calculated meclofenamic acid-
sensitive current are shown in Ba and b, respectively). 
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5.10. Genetic suppression of KCNQ3 influences M-channels currents 
In order to evaluate the extent to which KCNQ3 contributes to the M-current, VC 
experiments were performed in the VB TC neurons of mice that were deficient for one allele 
of KCNQ3 (KCNQ3+/- ). In these heterozygous mice, retigabine- and XE991-evoked effects 
were much smaller compared to the results obtained from the wild type (WT) animals 
(control, 100 ± 8.5 %; retigabine, 123.8 ± 14.5 %; retigabine + XE991, 116 ± 13.7 %; 
Repeated Measures ANOVA, F (2, 16) = 5.1, p= 0.0193; Newman-Keuls post-hoc test: 
retigabine vs. control: #p< 0.05; n = 9/2; Fig. 22A). Amplitudes and kinetics of the evoked 
current are depicted in Fig. 22Ba and Bb. Moreover, the amplitudes of the retigabine-sensitive 
currents measured in KCNQ3+/- and WT mice were significantly different (retigabine WT + 
62.8 ± 9.2 %; retigabine KCNQ3+/-, 23.8 ± 14.5 %; unpaired t-test; t = 2.4, *p = 0.0271; n = 
13/4 and n = 9/2 respectively; Fig. 22C). 
 
 
Table 1. Summary of the characteristics of the M-current in VB TC neurons, including results of the 
pharmachological modulation.  
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5.11. Different roles of M-channel subunits in modulation of the M-current 
The findings from KCNQ3+/- mice and evidence from previous studies show that differences 
in the current amplitude may be caused by different subunit composition of the channel. This 
warranted further experiments which were performed in collaboration with the Institute of 
Physiology of the Philipps University Marburg (Head of the department: Prof. Dr. Oliver). 
We used CHO heterologous expression system to co-express KCNQ2 and KCNQ3 in three 
different concentration ratios of the transfection vector: KCNQ2/3 1:1, 9:1 and 1:9. Expressed 
channels were challenged by a series of hyperpolarizing and depolarizing voltage steps (from 
Fig. 22. Loss of KCNQ3 subunit decreases M-current amplitude. In KCNQ3+/- mice the application of 
retigabine induces a significant increase in current amplitude (A; retigabine vs. control, #p< 0.05; n = 9/2) 
Example traces show the clear M-current
 
characteristics in the sensitive component of the current (Bb). C 
shows that the effect induced by retigabine is significantly more prominent in WT (*p < 0.05; n = 13/4 and n 
= 9/2 respectively). 
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-100 mV to +40 mV in 20 mV increment) while the cell was held at -60 mV (see inset of Fig. 
23). Figs. 23A, B and C show a clear gradation in current amplitudes: KCNQ2/3 1:1 > 
KCNQ2/3 9:1 > KCNQ2/3 1:9. Furthermore, the current voltage relationship (I/V plot) 
obtained from cells with different ratios of KCNQ2 and KCNQ3 is shown in Fig. 23D, show 
typical voltage activation.  
To further assess the properties of monomeric channels, the CHO cells were transfected with 
the same concentration of either KCNQ2 or KCNQ3. By this, we were able to estimate the 
individual contribution of KCNQ2 and KCNQ3 to the current amplitude, at high and at low 
concentrations (data not shown). 
 
 
Fig. 23. M-channels expression in CHO cells. The expression of different ratios of KCNQ2 to KCNQ3 in 
CHO cells leads to differences in current amplitude in the following gradation: KCNQ2/3 1:1 > KCNQ2/3 
9:1 > KCNQ2/3 1:9, as shown in example traces A, B and C. The I/V plot of KCNQ2/3 1:1 shows the typical 
voltage activation (D). 
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5.12. The expression of KCNQ2 and KCNQ3 in VB is age-dependent 
PCR analysis was conducted in collaboration with Dr. Kanyshkova from Physiology I, 
University of Muenster, to check if KCNQ2 and KCNQ3 mRNAs are present in thalamic VB. 
Surprisingly, the analysis revealed also the mRNA expression of KCNQ4 (Fig. 24A). Then, 
additional immunohistochemical (IHC) stainings were performed to analyse the protein 
expression using specific antibodies against KCNQ2, KCNQ3 and KCNQ4 (Fig. 24B), and, 
while strong signal was observed for KCNQ2 and KCNQ3, no protein expression was found 
for KCNQ4. Moreover, further investigations, performed with two different secondary 
antibodies for KCNQ2 and KCNQ3, showed that they are co-expressed and co-localize in the 
membrane of VB TC neurons (Fig. 24C). The IHC staining has been performed at four 
postnatal ages (p10; p20; p30 and p90). Our staining revealed that KCNQ2 is already 
expressed at p10. However, the highest level of fluorescence is reached at p20 and this level 
of expression is maintained throughout the adulthood (Fig. 25). An opposite trend could be 
observed for KCNQ3, which is highly expressed in juvenile mice (p20 and p30), but not in 
adulthood (Fig. 26).  
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Fig. 24. Expression of KCNQ channels in the VB nucleus of thalamus. A shows the mRNA expression of 
KCNQ channel isoforms in thalamic VB nucleus. The bands corresponding to KCNQ2, KCNQ3 and 
KCNQ4 are very strong, whereas KCNQ1 and KCNQ5 are not detected. B shows the protein expression of 
KCNQ2 and KCNQ3 (but not KCNQ4) in mouse VB complex. NeuN is a specific marker for neuronal cells 
(green) and KCNQ2/3 channels are labelled in red. In the bottom row KCNQ4 is labelled in green and DAPI 
(blue) is used as cell marker (scale bar = 20 µm). C shows the co-expression of KCNQ2 and KCNQ3 in VB. 
All stainings were performed in mice at P20. 
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Fig. 25. Age profile of KCNQ2 channel expression in the VB nucleus of the thalamus. A, B, C and D 
show the expression of KCNQ2 channels in VB nucleus of the thalamus at different ages. The expression of 
this channel is strong at early post-natal stages. A developmental down-regulation of the channel can be 
observed with increasing age. In the panel at the bottom, a double staining with the dendritic marker is shown 
when the expression of KCNQ2 is maximal, at p20.  
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5.13. In vivo pharmacological modulation of KCNQ channels  
The characterization in vitro of the KCNQ channels, performed in the VB TC neurons, 
provided information concerning KCNQ channel expression, their subunit composition and 
Fig. 26. Age profile of KCNQ3 channel expression in the VB nucleus of thalamus. A, B, C and D show 
the expression of KCNQ3 channel in thalamus VB at different ages. The expression of this channel is strong 
at the beginning of the adulthood. A developmental up-regulation of the channel can be observed with 
increasing age. In the panel at the bottom, a double staining with the dendritic marker is shown at p20.  
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their sensitivity to given substances. However, the physiological role of KCNQ channels in 
the thalamus remains unclear. Several lines of evidence showed involvement of both VB 
complex and KCNQ channels in pain sensation modulation (Pozza et al. 2010; Linley et al., 
2008). The following in vivo study was designed in order to explore the contribution of 
KCNQ channels to thalamic sensory functions, in particular their involvement in 
discrimination and processing of thermal noxious stimuli. In collaboration with Dr. Hanna 
Szkudlarek (Institut of Phisiology I, University of Muenster), we performed hot plate test in 
freely behaving animals, which were implanted with intra-thalamic guide canulas, for local 
injections of substances (see Material and Methods). The hot plate test is an acute pain test 
using thermal pain stimuli evoked by heating a base plate to 55 ± 1°C. The latency to the 
appearance of pain related behaviours is then measured (jumping, licking, shaking of the fore- 
or back-paws are considered as pain-related behaviours; Crockett et al., 1976; Kuraishi et al., 
1983). The graph in Fig. 27 shows that the intra-thalamic injection of retigabine significantly 
increases the latency in the hot plate test compared to the latency observed during the control 
trials (300 nl, 3 mM in 0.1 % DMSO in 0.9 % NaCl; control, 6.7 ± 0.3 s; retigabine, 11.5 ± 
0.3 s). The intra-thalamic injection of the specific KCNQ channel blocker XE991 
significantly decreases the latency (300 nl, 2 mM in 0.9 % NaCl; control, 6.4 ± 0.4 s; XE991, 
4.0 ± 0.3 s). Moreover, the co-injection of XE991 and retigabine (300 nl, 2 mM and 3 mM, 
respectively) induced a slight change in the latency, which was not statistically significant 
(control, 5.5 ± 0.4 s; retigabine + XE991, 7.1 ± 0.7 s). Similarly, the injection of the vehicle 
(0.1% DMSO in 0.9 % NaCl) causes no significant change in the observed latency (control, 
7.2 ± 0.4 s; DMSO, 6.2 ± 0.4 s; Repeated Measures ANOVA; F (7, 48) = 26.38; p<0.001; 
Newman-Keuls post-hoc test: retigabine and XE991 vs. respective control: ***p < 0.001; 
retigabine vs. DMSO, XE991 and retigabine + XE991: p < 0.001; XE991 vs. DMSO, 
retigabine + XE991: p < 0.001; n = 7; Fig. 27). 
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The animals were subjected to the hot plate test twice (control and post-injection trial). To 
exclude the possibility that learning or conditioning mechanisms influenced the second 
performance, we performed the test in naïve, retigabine-injected animals which had not 
experienced the control trial. Importantly, the observed latencies to pain in these naïve, 
retigabine-injected animals were not different from the latencies observed in retigabine-
injected animals that had first been subjected to a control trial (naïve + ret, 10 ± 0.6 s; 
retigabine preceded by control, 11.5 ± 0.3 s).  
 
All the compounds were co-injected with the fluorescent dye Alexa 488 to track and verify 
the injections sites using a fluoresecent microscope. Only animals in which both inections site 
were within the VB complex  were taken for the statistica, Fig. 28  shows two example of  the 
histological verification: a correct and a non correct one (A and B, respectively). The 
histological evaluation of the animals used for the experiments presented in Fig. 27 is 
summarize in the scheme in Fig. 28C and D where different color codes correspond to the 
different inected compounds.  
Fig. 27. M-channel modulation influences the pain response in mice. The latency to pain-related 
behaviour in the hot plate test increased after intra-thalamic injection of retigabine. The injection of XE991 
alone decreases this latency and co-injection of the two compounds does not significantly change latency, nor 
does injection of the vehicle DMSO (***p < 0.001 retigabine and XE991 vs. respective control; n = 7). 
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5.14. Retigabine is not metabolized within 24 h in the mouse brain  
Previous reports suggest that retigabine is not fully metabolized within 24 h post-injection 
(Rundfeldt et al., 2000). To assess this possibility, we tested the animals 24 h after the first 
trial. Latency values (10.5 ± 0.3 s) were still increased, suggesting that retigabine is active 
after 24 h following the injection. Additionally, the effect of the co-injcetion was the same, 
either when XE991 was injected 24h after retigabine or co-injected simultaneously, the same 
day (retigabine day 1, 11.9 ± 2.8 s; XE991 injected one day afterwards, 7.6 ± 1.2 s; n = 5). 
 
Fig. 28. Histological verification of the injection site. To track and verify the injection site, the fluorescent 
indicator Alexa 488 was co-injected with all substances. Fluorescence microscopy also allowed to estimate 
the spatial distribution of the injected volume. A) example photomicrograph of injection site after preparation 
of coronal slices. Green fluorescence shows the spatial spread of the injected fluid (dashed line). The 
injection site was within the borders of VB. B) The injection site is not within the VB. In C and D is shown a 
schematic representation of all the verified injection sites within VB, for the difference injected compounds. 
Note the orientation legend: d (dorsal), v (ventral), m (medial), l (lateral). 
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5.15. Effect of a combined intra-thalamic and intra-peritoneal modulation on pain 
behaviour 
Next, we tested if the analgesic effects observed in animals after intra-thalamic injections of 
the different substances were comparable to the effects induced by a systemic administration 
of the same substances. In addition, we aimed to understand the role of thalamic KCNQ 
channels in pain processing performing simultaneously intra-thalamic and intra-peritoneal 
(i.p.) injection of substance evoking the opposite effect (opener and blocker). 
In a first series of experiments, the animals were tested under control conditions and then, 
simultaneously injected with retigabine applied i.p (0.5 mg/ml) and with XE991 applied intra-
thalamically (2 mM, 300 nl). This manipulation, did not cause changes in the latency (control, 
7.2 ± 0.7 s; after injections, 7.6 ± 1.8 s; paired t-test, t = 0.23; p = 0.83, n = 4). In one animal 
of this group, the XE991 injection site was not located in the VB region and a big increase in 
the latency was observed, probably reflecting only the retigabine effect (latency = 20.3 s). 
In a second series of animals, XE991 (2 mg/kg) was injected i.p. and retigabine (3 mM, 
300 nl) was injected intra-thalamically. Under these conditions, no significant change in the 
latency occurred (control, 8.9 ± 0.1 s; after injections, 9.6 ± 4 s; n = 2). The sole i.p. injection 
of XE991 was able to decrease the latency compared to the control trial (control, 5.3 s; 
XE991, 3.3 s). 
Control experiments showed that the intra-thalamic injection of DMSO (0.1 % in 0.9 % NaCl, 
300 nl) does not affect the action of an i.p. injection of retigabine on hot plate pain behaviour 
latencies (control, 6 ± 0.6 s; retigabine, 15.3 ± 2 s; paired t-test, t = 6.4, p = 0.02; n = 3). 
 
5.16. The analgesic effect of retigabine in comparison to known analgesic drugs 
In the following, two well known analgesic compounds were used: the µ-opioid receptor 
agonist DAMGO (1 µM, 300 nl, in 0.9 % NaCl) and the GABAergic agonist muscimol (0.3 
nM, 300 nl, in 0.9 % NaCl). Both compounds affectively increased the latency in the hot plate 
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test (retigabine, 11.5 ± 0.3 s; DAMGO, 15.8 ±1.3 s; muscimol, 13.3 ± 1.61 s; one way 
ANOVA, F(5, 29) = 22.13, p < 0.0001; Tukey post hoc test: DAMGO, muscimol and 
retigabine vs. respective controls: p < 0.001; retigabine vs. DAMGO: p < 0.01; n = 4, 6, 7; 
Fig. 29). 
 
 
 
5.17. β-endorphin can modulate pain response 
Our in vitro patch-clamp experiments suggested β-endorphin as a possible endogenous 
modulator of KCNQ channels. Therefore we tested this opioid-like compound in freely 
behaving animals. The intra-thalamic injection of β-endorphin increased the latency in the hot 
plate test (control, 7.4 ± 0.3 s; β-endorphin, 10.2 ± 0.7 s; n = 10) and that effect was partially 
reversed by co-application with XE991 (control, 9.1 ± 1.3 s; β-endorphin + XE991, 6.5 ± 1.6 
s; n = 2; One way ANOVA, F (3, 23) = 4.67, p = 0.0124; Tukey post hoc test: β-endorphin vs. 
control: *p < 0.05; Fig. 30). Nevertheless, this finding does not necessarily imply an 
Fig. 29. Comparison of the effect of retigabine on pain threshold to the effect of other analgesic 
compounds. The intra-thalamic injection of the analgesic compounds DAMGO and muscimol (an opioid-
like compound and GABAergic agonist, respectively) significantly increase the latency on the hot plate test 
compared to respective controls (DAMGO, muscimol and retigabine vs. respective controls: ***p < 0.001). 
The effects of retigabine and muscimol are similar whereas the effect of DAMGO is significantly larger 
compared to the retigabine-induced effect (p < 0.01). 
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involvement of KCNQ channels since, β-endorphin could induce the effect via activation of 
other channels. 
 
 
5.18. Physiological release of β-endorphin does not affect KCNQ channel behaviour 
β-endorphin plays a role in the modulation of pain sensation (present study, Bach, 1997; 
Tseng, 2001). In the following experiments we aimed to assess the effect of endogenous β-
endorphin production on pain sensation in vivo and M-current amplitudes ex vivo. Therefore, 
we developed a protocol for triggering a physiological release of β-endorphin. The protocol 
included a 7-day training consisting of 20 minutes daily running in a running wheel, followed 
by enriched dietary supplement composed of milk and chocolate. Both procedures are known 
to induce the release of β-endorphin in mice (Dum et al., 1983). At the end of the training 
week, the animals were tested in the hot plate test. Analysis of the obtained results revealed 
no change in the latency (7.5 ± 1.4 s; n = 6). In line with this result, no changes in M-current 
properties were found during ex vivo recordings performed in VC mode (data not shown). 
Despite the lack of effect on the latency and on the M-current amplitude, we could show in 
the Enzyme Linked-Immunoabsorbent Assay (ELISA) that physical exercise combined with 
Fig. 30. β-endorphin modulates pain response in the hot plate test. The intra-thalamic injection of β-
endorphin induces an increase in the latency compared to the control response, while the co-injection of β-
endorphin and XE991 decreases the latency. 
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especially palatable food induced an increase of endogenous β-endorphin levels in the plasma 
but not in the thalamic tissue (Table 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. The concentration of β-endorphin in thalamus and in the blood plasma in control animals compared 
to trained animals (“runners”). A nominal increase in the β-endorphin concentration could be observed in the 
“runners” group compared to control in the plasma but not in thalamus (control; n =2, runners: n = 4). 
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6. Discussion 
For decades, the assumption that KCNQ channels are not functionally relevant for thalamic 
cell functioning was generally accepted among researchers. The main reason for this 
consideration was related to the lack of spike frequency adaptation in TC neurons, a hallmark 
of neurons with functional M-current (Adams and Brown, 1982; Jentsch, 2000). However, the 
work presented here disproves this generally accepted assumption. For the first time, 
consistent evidence for the mRNA and protein expression of KCNQ channels as well as 
functional M-current in thalamic VB neurons is presented. We show that these channels play 
an important role in regulating cell excitability. Moreover, they are able to regulate changes in 
the thalamic firing pattern during tonic and burst firing mode. In in vivo experiments, we 
demonstrate that the modulation of KCNQ channels in VB neurons is important for the 
regulation of pain sensation. The findings presented herein provide a new perspective on pain 
information processing in the thalamic VB, and we suggest KCNQ channels in the thalamus 
as new possible candidate in pain therapy. 
 
6.1. KCNQ channels are expressed and functionally active in thalamus VB 
KCNQ channels have been identified and characterized in PNS as well as in many CNS 
regions. Evidence for KCNQ2 (immunoreactivity) and for KCNQ3 (in situ hybridization) 
expression has been detected in hippocampus, cortex and thalamus (in the latter, mainly in the 
NRT and in the somato-sensory thalamus; Cooper et al., 2001; Geiger et al., 2006; Saganich 
et al., 2001). Our results corroborate these findings. We observed clear signals for KCNQ2 
and KCNQ3 mRNA and protein expression in PCR studies and IHC experiments, 
respectively. Despite previous expression studies, revealing clear signals of KCNQ channel 
expression in the thalamus, rather little evidence for a possible functional role of these 
channels in this brain region has been presented yet. In this respect, the expression of KCNQ2 
channels in the NRT, a region controlling thalamic oscillation, was described and the authors 
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speculated about the possibility of depolarizing NRT cells by inhibition of KCNQ channels 
(Cooper et al., 2001; Kasten et al., 2007).  
 
The result obtained in the course of this study verified protein expression of KCNQ channels. 
In order to assess their functional role in the thalamus, we performed an electrophysiological 
characterization of these channels by application of the KCNQ channel opener retigabine, 
which is considered one of the most effective and specific, among the openers, for the 
subunits 2-5 (the lack of effect on Ca2+ currents corroborates the specificity of retigabine, see 
Fig. 13; see also Tatulian and Brown, 2003; Gunthorpe et al., 2012), and by application of the 
specific blocker XE991 (Rivera-Arconada et al., 2005). In the present study, the application of 
the specific blocker was a constant procedure. In fact, the application of the opener supplies 
information about the presence of the channels in the region of interest, while the application 
of the specific blocker, in combination with the opener or alone, prior the opener application, 
allows assessing the specificity of the drug and, therefore, the specificity of our experimental 
approach.  
In VC experiments, the application of retigabine evokes a non-inactivating low-threshold K+ 
current (see Figs. 4B and 5A). The retigabine- sensitive component of the current show 
typical kinetics of an M-current (see Fig. 5B): slow activation and de-activation and no-
discernible inactivation as reviewed by Brown and colleagues (2009). On the other hand, the 
application of the blocker XE991 during control conditions decreased a current with very 
similar properties, although to a smaller extent in comparison to the retigabine-activated 
current (see Fig. 5C). These voltage-clamp experiments demonstrated that M-current is 
present in the VB nucleus. Nevertheless, at RMP, its presence is less obvious, because only a 
small number of the channels is active at this potential, as shown by the small effect induced 
by the blocker alone, during control conditions (see Fig. 5). This finding is fully supported by 
the literature which reports a similar small effect of M-current blockers at RMP values in cell 
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cultures and hippocampal neurons (Tatulian et al., 2001; Otto et al., 2002; Yue and Yaari, 
2004). In the same studies, the authors showed that M-current activation influenced neuronal 
firing properties by reducing the neuronal subthreshold excitability, thus, facilitating the rise 
of one or more action potentials, triggered by a small depolarization. Our results, obtained 
from current clamp experiments, suggest a similar effect on the firing properties of TC 
neurons. The application of the specific activator retigabine, causes a reduced number of 
stimulus-evoked action potentials. On the other hand, the application of the blocker XE991 
causes an increased number of stimulus-evoked action potentials thereby affecting the tonic 
firing mode of TC neurons (see Figs 6 and 7).  
The modulation of KCNQ channels in TC neurons also affects the burst firing mode in a 
significant way when it is elicited by injection of a short depolarizing pulse from 
hyperpolarized membrane potentials (see Fig. 8). The application of retigabine reduces the 
number of Na+ dependent action potentials crowning the Ca2+ spike, while the application of 
XE991 increases this number. This is the first evidence of M-current induced effects on tonic 
and burst firing in VB TC neurons. Previous studies in LD TC neurons (Kasten et al., 2007) 
and in hippocampal neurons (Yue and Yaari, 2004) already showed that retigabine attenuates 
high frequency or burst firing evoked by prolonged depolarizing stimuli. It was assumed that 
this effect was related to a modulation of KCNQ channels by two mechanisms involved in of 
the action potential rise: a facilitation of the afterdepolarization phase after XE991 application 
(when the channels are closed) and a prolongation of the middle after hyperpolarization 
(mAHP) phase, observed after retigabine application, with the latter reducing the maximal 
firing rate (Storm, 1989; Gunthorpe et al., 2012).  
Taken together, we can conclude that the expression of KCNQ channels in the thalamus has 
an important functional impact on the excitability of TC neurons. As with cortical and 
hippocampal neurons, M-current hyperpolarizes TC neurons in response to a depolarizing 
stimulus and tunes the neurons’s response (Hetka et al., 1999; Kasten et al., 2007). In fact, 
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this physiological role was described as “neuronal brake” from Brown (1982) and its removal 
“tunes up” the neuron leading to an alteration in the firing properties (Brown et al., 1982). 
Such a functionally important control mechanism serves a different role in the thalamus, 
where the intrinsic properties and peculiar anatomical connections of TC neurons contribute 
to the occurrence and maintenance of the two firing patterns. In fact, the change in their firing 
rate code is responsible of the typical TC neuron relay function that consists in discriminating 
information (somato-sensory and motoric informations), eventually conveyed to the cortex or 
to other high brain regions. 
 
M-current was originally described as muscarine-sensitive current (Brown, 1982; Adams and 
Brown, 1982), and in the present study, muscarinic modulation of KCNQ channels has been 
demonstrated using the muscarinic agonists oxotremorine-M and carbachol, which inhibit M-
current following previous current activation by retigabine (see Figs. 9 and 10). Muscarinic 
agonists modulate KCNQ channels via activation of second messenger cascades (Selyanko et 
al., 1992). In line with this, the application of the specific blocker XE991 exerts a stronger 
effect, most likely via a direct blockade, compared to Oxo-M or carbachol, that do not directly 
bind to the KCNQ channels. The release of acetylcholine in the thalamus from the brainstem 
ascending fibres directly regulates the shift between the two firing modes, promoting the tonic 
firing when the M1 and M3 muscarinic receptors are activated (McCormick., 1993; Steriade 
et al., 1993; Bista et al., 2012) and bursting when M2 receptors are activated (McCormick and 
Prince, 1986). This supports our hypothesis of KCNQ channels being important modulators in 
the somato-sensory system. In this respect, it is important to point out that KCNQ channels 
are involved in regulation of hippocampal oscillation during sleep and thus, they are inhibited 
during wakefulness, this evidence supports the role of these channels in regulating TC 
excitability and their firing modes (Hu et al., 2009). 
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6.2. Endogenous modulation of M-channels 
The present work has demonstrated that KCNQ channels are expressed and conduct the M-
current in thalamic neurons of the VB. Given the rather low basal activity in VB neurons and 
the inhibition of KCNQ channels by transmitters of the ascending brainstem system, the 
question arising is under which conditions these channels exert a strong functional impact. 
These questions may be answered by the identification of endogenous compounds that are 
able to activate the otherwise masked M-current in VB neurons. Previous studies identified a 
multitude of endogenous compounds active in pain sensation, which modulate M-channels in 
different brain regions. Thalamic VB neurons were already shown to be sensitive to opioid 
and opioid-like substances (Benoist et al., 1983; Okuyama et al., 1985), therefore, we here 
concentrated on those substances that have been associated with central pain procession.  
Nociceptin is an opioid-like compound binding to a specific opioid-like receptor (OLR; Meis 
et al., 2003) and Leu-enkephalin is an opioid that binds to µ- and δ-opioid receptors (Moore et 
al., 1994). Both compounds were shown to enhance a K+ current (M-current was among 
them) in the hippocampus in vitro (Madamba et al. 1999; Meis et al., 2003; Inyushkin, 2005). 
In voltage-clamp recordings from VB neurons shown in this study, leu-enkephalin and 
nociceptin activated an outward current sensitive to XE991 that cannot be considered an M-
current because of the different kinetics showed by the sensitive components of the current 
(see Figs. 15 and 17). Similar results were obtained from the application of dynorphin A and 
β-endorphin (see Figs. 14 and 16), only some of the TC neurons responded to substance 
application in a way that resembled M-current. This set of experiments reveleaded a kind of 
unspecific effect of XE991 application, which is decreasing evoked outward currents which 
either do not show M-current kinetics or only resemble them. Such effect could be explained 
by taking into consideration that the activation of the opioid receptors may influence M-
current kinetics or that we observed due different effects: the increment in the outward current 
due to additional K+ currents, probably conducted by inward-rectifier potassium channels 
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(Meis et al., 2003; Amano et al., 2000) and the XE991 effect on the basal M-current. Many 
factors could contribute to this result, and further investigation will be necessary. 
Although an endogenous compound for KCNQ channel activation could not be identified, an 
endogenous compound that is known to inhibit the M-current is acetylcholine (ACh). 
Cholinergic projections from the brainstem massively innervate thalamic cells. Thereby, they 
influence the regulation of sleep and wakefulness, memory and sensory cognition (Steriade et 
al., 1988). More recently, a number of studies have shown a strong participation of muscarinic 
and nicotinic ACh receptors in pain modulation at the peripheral level (Ueda et al., 2011; 
Motta et al., 2011). However, their role in the central nervous system is still unclear. The 
presence of KNCQ channels in the thalamus and their sensitivity to the muscarinic receptor 
activation could play a role in somato-sensory discrimination at the central level.  
 
6.3. Exogenous modulation of M-channels in the mouse VB 
6.3.1. Specific KCNQ modulators regulate M-channels 
Based on the inconclusive findings discussed in the literature above and the ambigous results 
observed after the application of β-endorphin and dynorphin A (discussed in the previous 
paragraph), the next step was to investigate to which extent this lack of clarity may depend on 
differences in the channel subunit composition in different brain areas. Therefore, we tried to 
assess the channel subunit expression by applying selective agonists of different KCNQ 
subunits. A large number of different and specific synthetic modulators of M-current are 
known (Wulff et al., 2009). None of these compounds have yet been tested on VB neurons.  
The effects observed for ICA27243, a selective enhancer of KCNQ2 and KCNQ3 heteromeric 
channels, and maxipost, specific activator of KCNQ4 and KCNQ5 subunits, in VB, are 
similar to previous data obtained in the presence of retigabine (Dalby-Brown et al., 2005). 
Although the magnitude of the effect is smaller for ICA27243 and maxipost, the sensitive 
components of the current clearly reveal slow activation and deactivation (see Figs. 18 and 
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19). These features are typical M-current kinetics, which suggests that M-current of thalamic 
VB neurons is mediated by both hetero- and/or homomeric channels composed of 
KCNQ2/3/4. Similar results were already published for striatum-neurons where the effects of 
ICA27243 and maxipost were weaker compared to retigabine, but both compounds have 
previously been considered good tools to distinguish between the different channel subtypes 
(Blom et al., 2010). Indeed, in this study they were very useful to assess from the 
electrophysiological point of view, that the heteromeric channel formed by KCNQ2 and 
KCNQ3, is abundant and functioning in VB, supporting our IHC findings on the protein 
expression level. Additionally, we can conclude that KCNQ4 and maybe KCNQ5 give some 
contribution to the M-current, as suggested by the effect of maxipost. 
 
6.3.2. Specific analgesic and anti-inflammatory compounds regulate M-channels 
The hypothesised role of M-channels in regulating the pain sensation still remains unclear. So 
far, there are only a few hints pointing to a participation of KCNQ channels in acute, chronic 
and inflammatory pain sensation (Blackburn-Munro et al., 2003, 2005; Dost et al., 2003; 
Takeda et al., 2011). Many of the novel synthesised KCNQ channel modulators (ICA27243, 
maxipost; Leventhal et al., 2007; Mark et al., 2007), as well as some already known 
compounds (diclofenac, meclofenamic acid) showed analgesic effects in different pain and 
inflammation animal models (Wulff et al. 2009). The ability of diclofenac and meclofenamic 
acid to enhance M-channels has been demonstrated before (Peretz et al., 2005). Here, both 
compounds are tested for the first time in the VB. Indeed, diclofenac and meclofenamic acid 
specifically modulate KCNQ2 and KCNQ3 channels. Their effect, in particular the one 
induced by diclofenac, is very strong and specific (see Figs. 20, 21). This was confirmed by 
blocking KCNQ channels before diclofenac application thereby preventing all M-channel 
activation. The possibility that other K+ currents, such as IA and IK, could contribute to this 
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effect, was also excluded by experiments in which both currents were blocked by 4-AP and 
TEA in concentrations not influencing M-current (see Fig. 20C). 
Considering all the findings in vitro, it is concluded that KCNQ channels in the thalamus are 
expressed both as homo- and heteromeric channels and can be activated by analgesic drugs. 
This supports the presumed role of thalamic M-channels in central pain sensation. The tested 
compounds can overcome the physiologic inhibition of M-channels (Linley et al., 2012). 
Consequently, these channels might act as targets for a future therapeutic strategy in pain and 
inflammatory pain treatment.  
 
6.4. KCNQ channels modulate acute pain sensation in freely behaving mice 
To further confirm our hypothesis and to understand if channel activation or inhibition is 
required for pain sensation in VB, the in vitro findings were translated into an in vivo model. 
The experiments were designed according to previous findings showing that the injection of 
opioid-like compounds into the VB induce relief and decrease in pain related behaviour 
(Porro et al., 2003; Potes et al., 2006; Pozza et al., 2010). To investigate the effect of KCNQ 
channel modulation in freely behaving animals, the hot plate test was used (55 °C) as cute 
pain model assay. Using a small Hamilton syringe, compounds were injected into the VB via 
a guide canula. The animals were then tested twice, i.e. before and after intra-thalamic 
injection of the substance, and the latency was defined as the time elapsed from the placement 
of the animal onto the plate until the time when the first pain behaviour was noticed (see 
Material and Methods). The experiment showed a clear effect of retigabine and XE991 on the 
latency to pain behaviour during the hot plate test: an increase in the case of retigabine and a 
decrease in the case of XE991 (see Fig. 27). XE991 partially or fully antagonised the 
analgesic effect of retigabine in animals injected with both XE991 and retigabine (see Fig. 27, 
see also Dost et al. 2004). It is concluded that KCNQ channels play an important role in 
modulating thermal acute pain discrimination. This role of KCNQ channels is neither well 
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known nor consistently documented in the literature; most of the studies focus on their role in 
neuropathic pain (Rivera-Arconada et al., 2009; Rose et al., 2011). Indeed, the effect of a 
pharmacological modulation of KCNQ channels on acute pain seems to be comparable to the 
effects of well known analgesic compounds, such as DAMGO and muscimol, after intra-
thalamic injection (see Fig. 29), supporting the findings in vitro and the role of these channels 
as possible therapeutic targets in pain therapy.  
 
6.5. The activation of the relay VB complex is required for pain sensation mediated 
by M-channels 
The VB complex is considered as the relay nucleus for somato-sensory information, such as 
nociceptive, tactile and kinaesthetic input, and couples the periphery to the cortex 
(Groenewegen and Witter, 2004). Because of that, KCNQ modulators were injected in other 
brain regions than the VB complex as negative control experiments (see Fig. 28). In those 
cases, there was no effect on the latency to pain behaviour, showing that the modulation of 
pain sensation via KCNQ channels is a VB-specific effect. As an additional control, 
simultaneous systemic and thalamic injections of retigabine and XE991 were performed in 
order to compare the effects induced by the two compounds in the periphery and at a central 
level, respectively. During the hot plate test, the injection of retigabine into the thalamus was 
antagonized by a systemic injection of XE991, and vice versa. However, no antagonism is 
observed when the injection site in the brain was not the VB. This suggests that there is a 
specific involvement of the VB complex in the modulation of pain perception, and that such a 
modulation requires the activation of KCNQ channels. Moreover, it shows that the drugs, 
when directly injected into the brain region of interest, remain largely confined into the 
injection site. 
Although these experiments depict a very clear scenario including VB neurons, pain sensation 
and KCNQ channels, many aspects of this regulation remain unknown. The experimental 
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setup applied in this study does not enable to discriminate between changes in pain threshold 
or in sensation per se. Both will evoke an increased latency. Additional experiments will be 
necessary to test compound effects in vivo in KCNQ2 and/or KCNQ3 deficient mice. 
Alternatively, the same hot plate test can be performed before and after retigabine injection, 
starting at a temperature that does not cause pain. By gradually increasing the temperature the 
threshold can be assessed and any shift will be registered.  
Based on the data presented herein, these future experiments would further corroborate the 
hypothesis that KCNQ channels are viable targets for acute pain treatment. 
Taken together, the findings from the experiments in vitro and in vivo shed light on the 
functional role of M-channels in the thalamic VB complex. We showed that KCNQ channel 
activity influences tonic and burst firing of thalamic VB neurons. The increased burst activity 
after the activation of KCNQ channels and the consequent appearance of the anti-nociceptive 
effect upon thermal stimulation suggest that M-current affects pain sensation as well as the 
information relay of the VB complex to the cortex, normally associated to the tonic activity.  
 
6.6. A possible functional meaning for a difference in the channel subunit 
composition 
The IHC staining (see Figs. 25 and 26) shows a clear trend for the expression of the subunits 
KCNQ2 and KCNQ3, respectively up- and down-regulated during the pre-weaning period 
and expressed at more stable levels during adulthood (after-weaning period). This subtype-
specific profile of development has been considered physiologic both in humans and rodents 
(Tinel et al., 1998; Kanaumi et al., 2008), and any alterations at the expression level was 
associated with the onset of more or less severe forms of epilepsy (Pena et al., 2006). The 
expression of KCNQ2 and KCNQ3 in the CHO heterologous expression system clearly 
showed that a change in subunit composition leads to alterations in the current amplitude (see 
Fig. 23). These findings are in line with previous studies that associated the differences in 
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current amplitudes to differences in subunit composition which, in VB, appear to be age-
dependent (Cooper et al., 2001; Hadley et al., 2003). Differences in the current amplitude 
could depend on differences in the expression of KCNQ genes In fact, this can produce 
different splice variants and consequently, different KCNQ2 subunits can combine with 
KCNQ3 to form the channel, as suggested by Pan and colleagues (2001).  
The role of different subunit composition potentially mediating different current amplitudes 
gives rise to speculations. Future experiments could clarify their role in somato-sensory 
perception processing such as learning and motor perception (Markus et al., 1987), circadian 
rhythms (Tamasy et al., 1980) and pain. Indeed, developmental differences were observable 
in the acute thermal pain sensation of young and adult rats. Markus and Petit (1987) 
performed the tail flick test, in which the tail of the animal is exposed to a strong red light 
with a constant intensity, and the latency to move the tail away from the light source was 
taken as readout. They found that the response to painful stimuli is shorter in young animals 
when compared to adults (Markus and Petit, 1987).  
Since KCNQ channels are involved in pain sensation (Rundfeldt et al., 2000, Delmas and 
Brown, 2005) and since the data presented herein show their particular expression pattern 
before and after weaning, a direct correlation may exist. Possibly, the difference in the onset 
of pain-related behaviour is influenced by KCNQ subunit compositions. It has been found 
previously that the age differences in pain responses were associated to incomplete maturation 
of the neuroanatomical and neurochemical systems (Ba and Seri, 1993; Falcon et al., 1996). 
In our case, the developmental profile of the channels has been shown in in vitro experiments, 
whereas the involvement of the channels in acute thermal pain sensation was shown in in vivo 
experiment. Altogether, the findings support the suggested hypothesis of a KCNQ channel-
dependent modulation of pain sensation in VB neurons.  
For future investigations, the experiments on the hot plate could be performed with animals of 
different ages in order to test possible developmental differences. A pharmacological 
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modulation on the same animals could be tested simultaneously. Nevertheless, brain surgery 
on young animals is difficult and rarely put into practice. In general, the study presented 
herein raises many questions concerning the pain sensation in rodents, but also in human 
neonates and infants. In order to improve pain treatment in children and adolescents, human 
ability to perceive and handle pain stimuli should be addressed in future studies.  
 
6.7. Concluding remarks 
KCNQ channels are involved in the modulation of pain sensation and in regulating cellular 
excitability, but such an effect can only occur when the channels are activated. 
Experimentally, this was achieved by the application of retigabine and typical analgesics. The 
effect of the specific blocker XE991 suggests that these channels were partially activated at 
RMP. This particular aspect of KCNQ channel activation may depend on the modulating 
muscarinic pathway, which most likely inhibits the current during wakefulness, favouring 
tonic firing and the relay function of TC neurons. In this scenario, extrinsic stimuli, such as 
acute thermal noxae, are required in order to open the channels. This would then cause a 
burst-like firing, which may underlie the analgesic effect observed in the hot plate test. It is 
likely that KCNQ channels are involved in a physiological response, like pain behaviour, 
which, under pathophsiological conditions, may alter the channels' function. Unfortunately, 
the physiological conditions activating KCNQ channels in the thalamus are still unknown. 
Moreover, the knowledge about the pathophysiology of these channels, which is commonly a 
starting point to understand the physiological mechanisms, is still insufficient. Further and 
more detailed experiments, both in vitro and in vivo, will be necessary to clarify this. 
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8. Abbreviations 
5-HT 
ACh 
AChR 
ACSF 
AD 
AT1 
B2  
BFNC 
Ca2+ 
CamK 
CChol 
CHO 
CNS 
Cs 
CsMetSO4 
DAMGO 
DMSO 
DRG 
EK 
ELISA 
GABA 
GABAA 
Glu 
IA 
IN 
5-hydroxy thyrosine 
Acetylcholine 
Acetylcholine receptor 
Artificial Cerebro-Spinal Fluid 
Antero-dorsal 
Angiotensin receptor type 1 
Bradykinin receptor type 2 
Benignal Familial Neonatal Convulsion 
Calcium 
Calcium Calmodulin Kinase 
Carbachol 
Chinese Hamster Ovarium 
Central Nervous System 
Membrane Capacitance 
Cesium Metal Sulphate 
[D-Ala2, N-MePhe4, Gly-ol]-enkephalin 
Dimethyl Sulfoxide 
Dorsal Root Ganglia 
Potassium Equilibrium Potential 
Enzyme-Linked Immuno-Adsorbent Assay 
Gamma amino-butyric acid 
GABA receptor type A 
Glutamate 
A-type potassium current 
Interneurons 
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LGN 
LQTS 
M1 
M3 
mGluR 
MGN 
NA 
Na+ 
NGF 
NMDA 
NRT 
Oxo-M 
P2Y 
PBS 
PFA  
PIP2 
PLC 
PNS 
PSLN 
Rin 
RMP 
SCG 
SEM 
SSR4 
TC  
TRG 
Lateral Geniculate Nucleus 
Long QT-Syndrome 
Muscarinic receptor type 1 
Muscarinic receptor type 3 
Metabotropic glutamate receptor 
Medial Geniculate Nucleus 
Noradrenaline 
Sodium 
Nerve growth factor 
N-Methyl, D-Aspartate 
Nucleus Reticularis Thalami 
Oxotremorine-M 
Purinergic receptor type 2 
Phosphate Buffered Saline 
Paraformaldehyde 
Phosphatidylinositol-4,5-biphosphate 
Phospholipase C 
Peripheral Nervous System 
Partial Sciatic Ligation of the Nerve 
Input Resistance 
Resting Membrane Potential 
Superior Cervical Ganglia 
Standard Error of the Mean 
Somatostatin receptor type 4 
Thalamo-cortical 
Trigeminal 
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TTX 
VA 
VB  
Vh 
VL  
VPL 
VPM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tetradotoxin 
Ventro-anterior 
Ventro-basal 
Holding Potential 
Ventro-lateral 
Ventro-postero lateral 
Ventro-postero medial 
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